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BCS                                                   Biopharmaceutics classification system 
GIT                                                    Gastrointestinal tract 
US-FDA                                             United states- Food & Drug administration 
L                                                         Litre 
ml                                                       millilitre 
hr                                                        hour 
min                                                     minute 
sec                                                       second 
gm                                                       gram 
mg                                                       milligram 
ADME                                                Absorption, Distribution, Metabolism & Excretion 
nm                                                       nanometre 
mm                                                      millimetre 
μm                                                       micrometre 
W/W                                                    weight/weight 
W/V                                                     weight/volume 
μg/ml                                                   microgram/milllilitre 
g/cc                                                      gram/cubiccentimetre 
m2/g                                                     Square metre/ gram 
#                                                           mesh size 
0c                                                          Degree celsius 
RPM                                                     Rotation per minute 
%                                                           Percentage 
API                                                       Active pharmaceutical ingredients 
ICH                                                       International conference on harmonization 
USP                                                       United states Pharmacopoeia 
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7. RESULTS AND DISCUSSION 
 The present study was undertaken to formulate Micronized Fenofibrate capsules. Fenofibrate 
belongs to BCS class-II drugs, having low solubility profile hence to improve the solubility of drug, 
different approaches were carried out in the formulations like Micronization, Addition of surfactant, 
optimization of binder with its concentration and Requirement of granulating fluid in the 
formulation. 
 The granules prepared in the present study by Wet granulation method have advantages over 
those prepared by other methods in terms of time and energy consumption, thus making it possible 
to formulate capsules at a lower cost. Due to their flexibility, hydrophilic polymer matrix systems 
are widely used in oral controlled drug delivery.  
  The study involved Micronization of drug, pre-formulation studies, Granulation steps, 
formulation and processing development along with evaluation of the capsules. 
7.1 MICRONIZATION OF DRUG: 
 Before going to pre-formulation studies, Fenofibrate drug was micronized from 15µ to 7µ using 
Jet milling at 7 to 8 bar atmospheric pressure by three repeated cycles. The evaluated parameters are 
described in Pre-formulation study. 
7.2 PRE-FORMULATION STUDIES: 
7.2.1 FT - INFRA RED SPECTROSCOPIC STUDIES: 
 By using FT IR technique, Non-Micronized and Micronized forms of API were identified by 
the frequency of the obtained peaks. The interpretations of the infra red spectrum of the drug are as 
follows.               Fig.8 FT-IR Spectrum of Non-micronised and Micronised drug 
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Specific fenofibrate peaks are observed at 2990, 1740, 1660 and 1600cm-1 and observed same in 
micronized formulation. 
7.2.2 DRUG-EXCIPIENT COMPATIBILITY STUDY: 
The Micronized fenofibrate was subjected to drug-excipients compatibility study with 
excipients like polyplasdone, microcrystalline cellulose, croscarmellose sodium, Poly vinyl pyrrolidine, 
starch, sodium lauryl sulfate, Aerosil, talc and magnesium stearate. The mixtures shown have no color 
change. 
7.2.3 PHYSICAL PARAMETERS: 
• The angle of repose for pure micronized drug was very less and hence the poor flow of the pure 
drug was exhibited. Also the compressibility index of the pure drug was found to be high, 
confirming that the drug has poor flow properties and compressibility. 
• Good flow of powders / granules is essential for capsule filling because the compressibility & 
flow properties of the drugs likely to influence the compression process in the preparation of 
capsules. In view of this the formulation were prepared by wet granulation technique to improve 
the flow as well as compressibility. 
• Loss on drying for micronized fenofibrate also show better results. 
 
Table:4 Physical parameter data for the pure drug 
     Density Parameters  Non-micronised After Ist cycle After2ndcycle    After3rdcycle 
   Bulk density (g/cc) 0.178 0.176 0.173  0.172 
  Tapped density (g/cc) 0.446 0.452 0.464  0.475 
Compressibility Index (%) 56.15 58.62 61.32  64.04 
  Hausner ratio 2.228 2.531 2.645  2.778 
   Angle of repose (θ )         12034’’  10054’’   10014’’    10024’’ 
    Loss on Drying(%) 0.415 0.408 0.398  0.406 
*Values mentioned are average of 3 determinations. 
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• When the Non-micronized and micronized drug was subjected for Aqueous solubility studies in 
which Non-micronized drug shows 0.25mg/ml having poor solubility as well as micronized 
drug shows 0.74mg/ml having improved solubility. 
 
7.2.4. ANALYTICAL PROPERTIES: 
 
 
 
 
 
 
From the standard calibration curve of drug it was concluded that drug obeys Beer-Lamberts 
law in concentration range of 2-16mcg/ml. Standard calibration graph and table were given below. 
                              Table:5 Standard calibration curve data for Fenofibrate API 
 
 
                                                  Fig.9 Calibration Graph Of Fenofibrate 
 
 
Concentration (µg/ml) Absorbance 
2 0.099 
4 0.199 
6 0.301 
8 0.400 
10 0.497 
12 0.598 
14 0.701 
16 0.803 
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The linear equation were obtained as  
Y=0.0501X - 0.0011, R2=0.9995 
       Correlation coefficient values indicated the linear correlation between concentration and 
absorbance. 
7.2.5. CRYSTAL PROPERTIES: 
• When the fenofibrate subjected to three cycling process results in decrease in particle size from 
14µm to 7µm and also increases in surface area after three cycling process. There is no change 
in melting point of fenofibrate after micronization. 
 
Table:6 Particle Size Parameters 
 
Particle 
Parameters 
Non-micronised After Ist cycle After2ndcycle After3rdcycle 
 
Particle 
size(µm) 
D (0.10) 1.323 0.946 0.871 0.800 
D (0.50) 7.004 5.141 4.451 3.925 
D (0.90) 13.713 10.362 9.517 7.832 
Surface area (m2/g) 0.76 1.12 1.48 1.94 
Melting point 80 79 81 80 
 
 
• The X-Ray diffraction pattern of the API sample and reference were overlapping with identical 
2θ and d-spacing values. This confirms the identification of the API. 
• The X-Ray diffraction pattern of micronized and Non-micronized API exhibited sharp, highly 
intense and less diffused peaks indicates the crystallinity nature of drug. The graphs are shown 
in Figure below. 
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Fig.10 XRD Pattern of Fenofibrate 
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7.3.1. FORMULATION SHEET 
Product: Fenofibrate capsules Batch size: 500 capsules 
Batch No: F01 Date: xx/yy/zz 
 
DISPENSING: 
 
Ingredients Grade Qty/unit in mg Qty/ batch in 
gm 
1.Fenofibrate Micronised 200.0 100.0 
2.Micro crystalline cellulose Avicel pH-101 33.5 16.75 
3.Starch Unipure F 12.0 6.0 
4.Cross povidone XL-10 16.5 8.25 
5.Poly Vinyl Pyrollidine K-25 12.0 6.0 
6.Crosscarmellose Sodium Ac-Di-Sol 12.0 6.0 
7.Sodium lauryl sulfate --- 9.0 4.5 
8.Collidal silicon dioxide Aerosil 200 1.0 0.5 
9.Talc --- 1.0 0.5 
10.Magnesium stearate --- 3.0 1.5 
11.Purified water --- q.s q.s 
 
GRANULATION: 
 
Equipment used: Rapid mixer granulator Volume: 8L Type: Wet method 
 
A) Sifting: 
Ingredients Qty taken Mesh size Ingredients Qty taken Mesh 
size 
1.Fenofibrate 100gm 40# 4.Cross povidone XL-10 6.0gm 40# 
2.MCC pH-101 13.50gm 40# 5.Ac-Di-Sol 6.0gm 40# 
3.Unipure starch 6.0gm 40# 6.Sodium lauryl sulfate 4.5gm 40# 
 
B) Dry mix: 
Sequence of addition:      Add 1+2+3+4 
Mixer blade    : ON Amperage: Slow Time: 10 min 
Chopper blade: OFF Amperage: --- Time: --- 
 
C) Binder preparation: 
               Add 6gm of PVP K-25 in 45gm of purified water and stir well with mechanical 
stirrer for 45 minutes. 
Total Water quantity:  42.5gm + 2.5gm Binder concentration(%w/w): 4.0% 
 
D) Wet granulation: 
Process Mixer blade Chopper blade Amperage Time 
Binder addition ON OFF Slow 1 min 30 sec 
Extra water adiition ON OFF Slow 30 sec 
After binder addition ON ON Slow 5 min 
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E) Wet sieving 
Equipment: Hand mill Screen size: 30# 
 
DRYING: 
 
Equipment: Fluidized bed dryer Temperature: 550c Time: 2hrs 
LOD: NMT 2.0%  (500c for 5min) 
 
A) Dry sieving: 
Equipment: Vibratory siever Sieve no: 30# 
Total Qty : 138.95 Qty retained: 50.48 Qty passed: 88.47 
 
EXTRA-GRANULATION: 
 
Ingredients Qty taken Mesh size Ingredients Qty taken Mesh 
size 
1.MCC pH-101 3.18gm 40# 3.Talc 0.48gm 40# 
2.Aerosil 200 0.48gm 40# 4.Cross povidone XL-10 2.20gm 40# 
Sequence of addition: Dried granules + Above meshed ingredients 
Equipment: Octagonal blender Rotation per minute: 15 Time: 20mins 
 
LUBRICATION: 
                  
Lubricator: Magnesium stearate Qty taken: 1.45gm Mesh size: 60# 
Sequence of addition: Addition of lubricator to extra granulated product 
Equipment: Octagonal blender Rotation per minute: 15 Time: 5mins 
 
Final weight of batch: 146.7gm 
 
 
Percentage yield: 97.8% 
 
CAPSULE FILLING: 
 
 
A) Capsule description: 
Capsule Size: ‘1’                         Colour                   Imprinting 
Body: Green Cap: Green Body: G Cap: G302 
Target wt: 300mg/capsule Wt. of empty capsule: 76 mg 
Total wt. of granules used: 146.7gm No. of capsules required: 500 
 
B) Observation 
Flow on plate: Good Pressing required: Two turns 
Fill Pressure: Normal 
 
No. of capsules filled: 490 
 
 
 
RESULTS AND DISCUSSION 
Department of Pharmaceutics, K.M. College of Pharmacy, Madurai.                    66 
 
7.3.2. FORMULATION SHEET 
Product: Fenofibrate capsules Batch size: 500 capsules 
Batch No: F02 Date: xx/yy/zz 
 
DISPENSING: 
 
Ingredients Grade Qty/unit in mg Qty/ batch in 
gm 
1.Fenofibrate Micronised 200.0 100.0 
2.Micro crystalline cellulose Avicel pH-101 27.5 13.75 
3.Starch Unipure F 12.0 6.0 
4.Cross povidone XL-10 16.5 8.25 
5.Poly Vinyl Pyrollidine K-25 18.0 9.0 
6.Crosscarmellose Sodium Ac-Di-Sol 12.0 6.0 
7.Sodium lauryl sulfate --- 9.0 4.5 
8.Collidal silicon dioxide Aerosil 200 1.0 0.5 
9.Talc --- 1.0 0.5 
10.Magnesium stearate --- 3.0 1.5 
11.Purified water --- q.s q.s 
 
GRANULATION: 
 
Equipment used: Rapid mixer granulator Volume: 8L Type: Wet method 
 
A) Sifting: 
Ingredients Qty taken Mesh size Ingredients Qty taken Mesh 
size 
1.Fenofibrate 100gm 40# 4.Cross povidone XL-10 6.0gm 40# 
2.MCC pH-101 10.50gm 40# 5.Ac-Di-Sol 6.0gm 40# 
3.Unipure starch 6.0gm 40# 6.Sodium lauryl sulfate 4.5gm 40# 
 
B) Dry mix: 
Sequence of addition:      Add 1+2+3+4 
Mixer blade    : ON Amperage: Slow Time: 10 min 
Chopper blade: OFF Amperage: --- Time: --- 
 
C) Binder preparation: 
               Add 9gm of PVP K-25 in 45gm of purified water and stir well with mechanical 
stirrer for 45 minutes. 
Total Water quantity:  42.5gm + 2.5gm Binder concentration(%w/w): 6.0% 
 
D) Wet granulation: 
Process Mixer blade Chopper blade Amperage Time 
Binder addition ON OFF Slow 1 min 30 sec 
Extra water adiition ON OFF Slow 30 sec 
After binder addition ON ON Slow 5 min 
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E) Wet sieving 
Equipment: Hand mill Screen size: 30# 
 
DRYING: 
 
Equipment: Fluidized bed dryer Temperature: 550c Time: 2hrs 
LOD: NMT 2.0%  (500c for 5min) 
 
A) Dry sieving: 
Equipment: Vibratory siever Sieve no: 30# 
Total Qty : 139.95 Qty retained: 52.65 Qty passed: 87.3 
 
EXTRA-GRANULATION: 
 
Ingredients Qty taken Mesh size Ingredients Qty taken Mesh 
size 
1.MCC pH-101 4.95gm 40# 3.Talc 0.49gm 40# 
2.Aerosil 200 0.49gm 40# 4.Cross povidone XL-10 2.20gm 40# 
Sequence of addition: Dried granules + Above meshed ingredients 
Equipment: Octagonal blender Rotation per minute: 15 Time: 20mins 
 
LUBRICATION: 
                  
Lubricator: Magnesium stearate Qty taken: 1.475gm Mesh size: 60# 
Sequence of addition: Addition of lubricator to extra granulated product 
Equipment: Octagonal blender Rotation per minute: 15 Time: 5mins 
 
Final weight of batch: 148.2gm 
 
 
Percentage yield: 98.8% 
 
CAPSULE FILLING: 
 
 
A) Capsule description: 
Capsule Size: ‘1’                         Colour                   Imprinting 
Body: Green Cap: Green Body: G Cap: G302 
Target wt: 300mg/capsule Wt. of empty capsule: 76 mg 
Total wt. of granules used: 148.2gm No. of capsules required: 500 
 
B) Observation 
Flow on plate: Good Pressing required: Two turns 
Fill Pressure: Normal 
 
No. of capsules filled: 494 
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7.3.3. FORMULATION SHEET 
Product: Fenofibrate capsules Batch size: 500 capsules 
Batch No: F03 Date: xx/yy/zz 
 
DISPENSING: 
 
Ingredients Grade Qty/unit in mg Qty/ batch in 
gm 
1.Fenofibrate Micronised 200.0 100.0 
2.Micro crystalline cellulose Avicel pH-101 21.5 10.75 
3.Starch Unipure F 12.0 6.0 
4.Cross povidone XL-10 16.5 8.25 
5.Poly Vinyl Pyrollidine K-25 24.0 12.0 
6.Crosscarmellose Sodium Ac-Di-Sol 12.0 6.0 
7.Sodium lauryl sulfate --- 9.0 4.5 
8.Collidal silicon dioxide Aerosil 200 1.0 0.5 
9.Talc --- 1.0 0.5 
10.Magnesium stearate --- 3.0 1.5 
11.Purified water --- q.s q.s 
 
GRANULATION: 
 
Equipment used: Rapid mixer granulator Volume: 10L Type: Wet method 
 
A) Sifting: 
Ingredients Qty taken Mesh size Ingredients Qty taken Mesh 
size 
1.Fenofibrate 100gm 40# 4.Cross povidone XL-10 6.0gm 40# 
2.MCC pH-101 7.50gm 40# 5.Ac-Di-Sol 6.0gm 40# 
3.Unipure starch 6.0gm 40# 6.Sodium lauryl sulfate 4.5gm 40# 
 
B) Dry mix: 
Sequence of addition:      Add 1+2+3+4 
Mixer blade    : ON Amperage: Slow Time: 10 min 
Chopper blade: OFF Amperage: --- Time: --- 
 
C) Binder preparation: 
               Add 12gm of PVP K-25 in 45gm of purified water and stir well with mechanical 
stirrer for 45 minutes. 
Total Water quantity:  42.5gm + 2.5gm Binder concentration(%w/w): 8.0% 
 
D) Wet granulation: 
Process Mixer blade Chopper blade Amperage Time 
Binder addition ON OFF Slow 1 min 30 sec 
Extra water adiition ON OFF Slow 30 sec 
After binder addition ON ON Slow 5 min 
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E) Wet sieving 
Equipment: Hand mill Screen size: 30# 
 
DRYING: 
 
Equipment: Fluidized bed dryer Temperature: 550c Time: 2hrs 
LOD: NMT 2.0%  (500c for 5min) 
 
A) Dry sieving: 
Equipment: Vibratory siever Sieve no: 30# 
Total Qty : 139.20 Qty retained: 57.10 Qty passed: 82.10 
 
EXTRA-GRANULATION: 
 
Ingredients Qty taken Mesh size Ingredients Qty taken Mesh 
size 
1.MCC pH-101 3.18gm 40# 3.Talc 0.48gm 40# 
2.Aerosil 200 0.48gm 40# 4.Cross povidone XL-10 2.20gm 40# 
Sequence of addition: Dried granules + Above meshed ingredients 
Equipment: Octagonal blender Rotation per minute: 15 Time: 20mins 
 
LUBRICATION: 
                  
Lubricator: Magnesium stearate Qty taken: 1.45gm Mesh size: 60# 
Sequence of addition: Addition of lubricator to extra granulated product 
Equipment: Octagonal blender Rotation per minute: 15 Time: 5mins 
 
Final weight of batch: 147.30gm 
 
 
Percentage yield: 98.2% 
 
CAPSULE FILLING: 
 
 
A) Capsule description: 
Capsule Size: ‘1’                         Colour                   Imprinting 
Body: Green Cap: Green Body: G Cap: G302 
Target wt: 300mg/capsule Wt. of empty capsule: 76 mg 
Total wt. of granules used: 147.3gm No. of capsules required: 500 
 
B) Observation 
Flow on plate: Good Pressing required: Two turns 
Fill Pressure: Normal 
 
No. of capsules filled: 491 
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7.3.4. FORMULATION SHEET 
Product: Fenofibrate capsules Batch size: 500 capsules 
Batch No: F04 Date: xx/yy/zz 
 
DISPENSING: 
 
Ingredients Grade Qty/unit in mg Qty/ batch in 
gm 
1.Fenofibrate Micronised 200.0 100.0 
2.Micro crystalline cellulose Avicel pH-101 27.5 13.75 
3.Starch Unipure F 12.0 6.0 
4.Cross povidone XL-10 16.5 8.25 
5.Poly Vinyl Pyrollidine K-25 18.0 9.0 
6.Crosscarmellose Sodium Ac-Di-Sol 12.0 6.0 
7.Sodium lauryl sulfate --- 9.0 4.5 
8.Collidal silicon dioxide Aerosil 200 1.0 0.5 
9.Talc --- 1.0 0.5 
10.Magnesium stearate --- 3.0 1.5 
11.Purified water --- q.s q.s 
 
GRANULATION: 
 
Equipment used: Rapid mixer granulator Volume: 8L Type: Wet method 
 
A) Sifting: 
Ingredients Qty taken Mesh size Ingredients Qty taken Mesh 
size 
1.Fenofibrate 100gm 40# 4.Cross povidone XL-10 6.0gm 40# 
2.MCC pH-101 10.50gm 40# 5.Ac-Di-Sol 6.0gm 40# 
3.Unipure starch 6.0gm 40# 6.Sodium lauryl sulfate --- --- 
 
B) Dry mix: 
Sequence of addition:      Add 1+2+3+4 
Mixer blade    : ON Amperage: Slow Time: 10 min 
Chopper blade: OFF Amperage: --- Time: --- 
 
C) Binder preparation: 
               Add 9gm of PVP K-25 and 4.5gm of SLS in 45gm of purified water and stir well 
with mechanical stirrer for 45 minutes. 
Total Water quantity:  42.5gm + 2.5gm Binder concentration(%w/w): 6.0% 
 
D) Wet granulation: 
Process Mixer blade Chopper blade Amperage Time 
Binder addition ON OFF Slow 1 min 30 sec 
Extra water adiition ON OFF Slow 30 sec 
After binder addition ON ON Slow 5 min 
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E) Wet sieving 
Equipment: Hand mill Screen size: 30# 
 
DRYING: 
 
Equipment: Fluidized bed dryer Temperature: 550c Time: 2hrs 
LOD: NMT 2.0%  (500c for 5min) 
 
A) Dry sieving: 
Equipment: Vibratory siever Sieve no: 30# 
Total Qty : 138.75 Qty retained: 52.55 Qty passed: 86.20 
 
EXTRA-GRANULATION: 
 
Ingredients Qty taken Mesh size Ingredients Qty taken Mesh 
size 
1.MCC pH-101 3.18gm 40# 3.Talc 0.48gm 40# 
2.Aerosil 200 0.48gm 40# 4.Cross povidone XL-10 2.20gm 40# 
Sequence of addition: Dried granules + Above meshed ingredients 
Equipment: Octagonal blender Rotation per minute: 15 Time: 20mins 
 
LUBRICATION: 
                  
Lubricator: Magnesium stearate Qty taken: 1.45gm Mesh size: 60# 
Sequence of addition: Addition of lubricator to extra granulated product 
Equipment: Octagonal blender Rotation per minute: 15 Time: 5mins 
 
Final weight of batch: 145.95gm 
 
 
Percentage yield: 97.3% 
 
CAPSULE FILLING: 
 
 
A) Capsule description: 
Capsule Size: ‘1’                         Colour                   Imprinting 
Body: Green Cap: Green Body: G Cap: G302 
Target wt: 300mg/capsule Wt. of empty capsule: 76 mg 
Total wt. of granules used: 145.95gm No. of capsules required: 500 
 
B) Observation 
Flow on plate: Good Pressing required: Two turns 
Fill Pressure: Normal 
 
No. of capsules filled: 486 
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7.3.5. FORMULATION SHEET 
Product: Fenofibrate capsules Batch size: 500 capsules 
Batch No: F05 Date: xx/yy/zz 
 
DISPENSING: 
 
Ingredients Grade Qty/unit in mg Qty/ batch in 
gm 
1.Fenofibrate Micronised 200.0 100.0 
2.Micro crystalline cellulose Avicel pH-101 27.5 13.75 
3.Starch Unipure F 12.0 6.0 
4.Cross povidone XL-10 16.5 8.25 
5.Poly Vinyl Pyrollidine K-25 18.0 9.0 
6.Crosscarmellose Sodium Ac-Di-Sol 12.0 6.0 
7.Sodium lauryl sulfate --- 9.0 4.5 
8.Collidal silicon dioxide Aerosil 200 1.0 0.5 
9.Talc --- 1.0 0.5 
10.Magnesium stearate --- 3.0 1.5 
11.Purified water --- q.s q.s 
 
GRANULATION: 
 
Equipment used: Rapid mixer granulator Volume: 8L Type: Wet method 
 
A) Sifting: 
Ingredients Qty taken Mesh size Ingredients Qty taken Mesh 
size 
1.Fenofibrate 100gm 40# 4.Cross povidone XL-10 6.0gm 40# 
2.MCC pH-101 10.50gm 40# 5.Ac-Di-Sol 6.0gm 40# 
3.Unipure starch 6.0gm 40# 6.Sodium lauryl sulfate 3.0gm 40# 
 
B) Dry mix: 
Sequence of addition:      Add 1+2+3+4 
Mixer blade    : ON Amperage: Slow Time: 10 min 
Chopper blade: OFF Amperage: --- Time: --- 
 
C) Binder preparation: 
               Add 9gm of PVP K-25 and 1.5gm of SLS in 45gm of purified water and stir well 
with mechanical stirrer for 45 minutes. 
Total Water quantity:  42.5gm + 2.5gm Binder concentration(%w/w): 6.0% 
 
D) Wet granulation: 
Process Mixer blade Chopper blade Amperage Time 
Binder addition ON OFF Slow 1 min 30 sec 
Extra water adiition ON OFF Slow 30 sec 
After binder addition ON ON Slow 5 min 
 
E) Wet sieving 
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Equipment: Hand mill Screen size: 30# 
 
DRYING: 
 
Equipment: Fluidized bed dryer Temperature: 550c Time: 2hrs 
LOD: NMT 2.0%  (500c for 5min) 
 
A) Dry sieving: 
Equipment: Vibratory siever Sieve no: 30# 
Total Qty : 139.55 Qty retained: 53.35 Qty passed: 86.20 
 
EXTRA-GRANULATION: 
 
Ingredients Qty taken Mesh size Ingredients Qty taken Mesh 
size 
1.MCC pH-101 4.95gm 40# 3.Talc 0.49gm 40# 
2.Aerosil 200 0.49gm 40# 4.Cross povidone XL-10 2.20gm 40# 
Sequence of addition: Dried granules + Above meshed ingredients 
Equipment: Octagonal blender Rotation per minute: 15 Time: 20mins 
 
LUBRICATION: 
                  
Lubricator: Magnesium stearate Qty taken: 1.475gm Mesh size: 60# 
Sequence of addition: Addition of lubricator to extra granulated product 
Equipment: Octagonal blender Rotation per minute: 15 Time: 5mins 
 
Final weight of batch: 147.60gm 
 
 
Percentage yield: 98.4% 
 
CAPSULE FILLING: 
 
 
A) Capsule description: 
Capsule Size: ‘1’                         Colour                   Imprinting 
Body: Green Cap: Green Body: G Cap: G302 
Target wt: 300mg/capsule Wt. of empty capsule: 76 mg 
Total wt. of granules used: 147.60gm No. of capsules required: 500 
 
B) Observation 
Flow on plate: Good Pressing required: Two turns 
Fill Pressure: Normal 
 
No. of capsules filled: 492 
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7.3.6. FORMULATION SHEET 
Product: Fenofibrate capsules Batch size: 500 capsules 
Batch No: F06 Date: xx/yy/zz 
 
 
DISPENSING: 
 
Ingredients Grade Qty/unit in mg Qty/ batch in 
gm 
1.Fenofibrate Micronised 200.0 100.0 
2.Micro crystalline cellulose Avicel pH-101 27.5 13.75 
3.Starch Unipure F 12.0 6.0 
4.Cross povidone XL-10 16.5 8.25 
5.Poly Vinyl Pyrollidine K-25 18.0 9.0 
6.Crosscarmellose Sodium Ac-Di-Sol 12.0 6.0 
7.Sodium lauryl sulfate --- 9.0 4.5 
8.Collidal silicon dioxide Aerosil 200 1.0 0.5 
9.Talc --- 1.0 0.5 
10.Magnesium stearate --- 3.0 1.5 
11.Purified water --- q.s q.s 
 
GRANULATION: 
 
Equipment used: Rapid mixer granulator Volume: 8L Type: Wet method 
 
A) Sifting: 
Ingredients Qty taken Mesh size Ingredients Qty taken Mesh 
size 
1.Fenofibrate 100gm 40# 4.Cross povidone XL-10 6.0gm 40# 
2.MCC pH-101 10.50gm 40# 5.Ac-Di-Sol 6.0gm 40# 
3.Unipure starch 6.0gm 40# 6.Sodium lauryl sulfate 1.5gm 40# 
 
B) Dry mix: 
Sequence of addition:      Add 1+2+3+4 
Mixer blade    : ON Amperage: Slow Time: 10 min 
Chopper blade: OFF Amperage: --- Time: --- 
 
C) Binder preparation: 
               Add 9gm of PVP K-25 and 3.0gm of SLS in 45gm of purified water and stir well 
with mechanical stirrer for 45 minutes. 
Total Water quantity:  42.5gm + 2.5gm Binder concentration(%w/w): 6.0% 
 
D) Wet granulation: 
Process Mixer blade Chopper blade Amperage Time 
Binder addition ON OFF Slow 1 min 30 sec 
Extra water adiition ON OFF Slow 30 sec 
After binder addition ON ON Slow 5 min 
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E) Wet sieving 
Equipment: Hand mill Screen size: 30# 
 
DRYING: 
 
Equipment: Fluidized bed dryer Temperature: 550c Time: 2hrs 
LOD: NMT 2.0%  (500c for 5min) 
 
A) Dry sieving: 
Equipment: Vibratory siever Sieve no: 30# 
Total Qty : 139.35 Qty retained: 53.25 Qty passed: 86.10 
 
EXTRA-GRANULATION: 
 
Ingredients Qty taken Mesh size Ingredients Qty taken Mesh 
size 
1.MCC pH-101 4.95gm 40# 3.Talc 0.49gm 40# 
2.Aerosil 200 0.49gm 40# 4.Cross povidone XL-10 2.20gm 40# 
Sequence of addition: Dried granules + Above meshed ingredients 
Equipment: Octagonal blender Rotation per minute: 15 Time: 20mins 
 
LUBRICATION: 
                  
Lubricator: Magnesium stearate Qty taken: 1.475gm Mesh size: 60# 
Sequence of addition: Addition of lubricator to extra granulated product 
Equipment: Octagonal blender Rotation per minute: 15 Time: 5mins 
 
Final weight of batch: 147.45gm 
 
 
Percentage yield: 98.3% 
 
CAPSULE FILLING: 
 
 
A) Capsule description: 
Capsule Size: ‘1’                         Colour                   Imprinting 
Body: Green Cap: Green Body: G Cap: G302 
Target wt: 300mg/capsule Wt. of empty capsule: 76 mg 
Total wt. of granules used: 147.60gm No. of capsules required: 500 
 
B) Observation 
Flow on plate: Good Pressing required: Two turns 
Fill Pressure: Normal 
 
No. of capsules filled: 492 
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7.3.7. FORMULATION SHEET 
Product: Fenofibrate capsules Batch size: 500 capsules 
Batch No: F07 Date: xx/yy/zz 
 
DISPENSING: 
 
Ingredients Grade Qty/unit in mg Qty/ batch in 
gm 
1.Fenofibrate Micronised 200.0 100.0 
2.Micro crystalline cellulose Avicel pH-101 27.5 13.75 
3.Starch Unipure F 12.0 6.0 
4.Cross povidone XL-10 16.5 8.25 
5.Poly Vinyl Pyrollidine K-25 18.0 9.0 
6.Crosscarmellose Sodium Ac-Di-Sol 12.0 6.0 
7.Sodium lauryl sulfate --- 9.0 4.5 
8.Collidal silicon dioxide Aerosil 200 1.0 0.5 
9.Talc --- 1.0 0.5 
10.Magnesium stearate --- 3.0 1.5 
11.Purified water --- q.s q.s 
 
GRANULATION: 
 
Equipment used: Rapid mixer granulator Volume: 8L Type: Wet method 
 
A) Sifting: 
Ingredients Qty taken Mesh size Ingredients Qty taken Mesh 
size 
1.Fenofibrate 100gm 40# 4.Cross povidone XL-10 6.0gm 40# 
2.MCC pH-101 10.50gm 40# 5.Ac-Di-Sol 6.0gm 40# 
3.Unipure starch 6.0gm 40# 6.Sodium lauryl sulfate 2.25gm 40# 
 
B) Dry mix: 
Sequence of addition:      Add 1+2+3+4 
Mixer blade    : ON Amperage: Slow Time: 10 min 
Chopper blade: OFF Amperage: --- Time: --- 
 
C) Binder preparation: 
               Add 9gm of PVP K-25 and 2.25gm of SLS in 45gm of purified water and stir well 
with mechanical stirrer for 45 minutes. 
Total Water quantity:  42.5gm + 2.5gm Binder concentration(%w/w): 6.0% 
 
D) Wet granulation: 
Process Mixer blade Chopper blade Amperage Time 
Binder addition ON OFF Slow 1 min 30 sec 
Extra water adiition ON OFF Slow 30 sec 
After binder addition ON ON Slow 5 min 
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E) Wet sieving 
Equipment: Hand mill Screen size: 30# 
 
DRYING: 
 
Equipment: Fluidized bed dryer Temperature: 550c Time: 2hrs 
LOD: NMT 2.0%  (500c for 5min) 
 
A) Dry sieving: 
Equipment: Vibratory siever Sieve no: 30# 
Total Qty : 139.15 Qty retained: 52.85 Qty passed: 86.30 
 
EXTRA-GRANULATION: 
 
Ingredients Qty taken Mesh size Ingredients Qty taken Mesh 
size 
1.MCC pH-101 4.95gm 40# 3.Talc 0.49gm 40# 
2.Aerosil 200 0.49gm 40# 4.Cross povidone XL-10 2.20gm 40# 
Sequence of addition: Dried granules + Above meshed ingredients 
Equipment: Octagonal blender Rotation per minute: 15 Time: 20mins 
 
LUBRICATION: 
                  
Lubricator: Magnesium stearate Qty taken: 1.475gm Mesh size: 60# 
Sequence of addition: Addition of lubricator to extra granulated product 
Equipment: Octagonal blender Rotation per minute: 15 Time: 5mins 
 
Final weight of batch: 147.15gm 
 
 
Percentage yield: 98.1% 
 
CAPSULE FILLING: 
 
 
A) Capsule description: 
Capsule Size: ‘1’                         Colour                   Imprinting 
Body: Green Cap: Green Body: G Cap: G302 
Target wt: 300mg/capsule Wt. of empty capsule: 76 mg 
Total wt. of granules used: 147.60gm No. of capsules required: 500 
 
B) Observation 
Flow on plate: Good Pressing required: Two turns 
Fill Pressure: Normal 
 
No. of capsules filled: 491 
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7.3.8. FORMULATION SHEET 
Product: Fenofibrate capsules Batch size: 500 capsules 
Batch No: F08 Date: xx/yy/zz 
 
DISPENSING: 
 
Ingredients Grade Qty/unit in mg Qty/ batch in 
gm 
1.Fenofibrate Micronised 200.0 100.0 
2.Micro crystalline cellulose Avicel pH-101 27.5 13.75 
3.Starch Unipure F 12.0 6.0 
4.Cross povidone XL-10 16.5 8.25 
5.Poly Vinyl Pyrollidine K-25 18.0 9.0 
6.Crosscarmellose Sodium Ac-Di-Sol 12.0 6.0 
7.Sodium lauryl sulfate --- 9.0 4.5 
8.Collidal silicon dioxide Aerosil 200 1.0 0.5 
9.Talc --- 1.0 0.5 
10.Magnesium stearate --- 3.0 1.5 
11.Purified water --- q.s q.s 
 
GRANULATION: 
 
Equipment used: Rapid mixer granulator Volume: 8L Type: Wet method 
 
A) Sifting: 
Ingredients Qty taken Mesh size Ingredients Qty taken Mesh 
size 
1.Fenofibrate 100gm 40# 4.Cross povidone XL-10 6.0gm 40# 
2.MCC pH-101 10.50gm 40# 5.Ac-Di-Sol 6.0gm 40# 
3.Unipure starch 6.0gm 40# 6.Sodium lauryl sulfate 1.5gm 40# 
 
B) Dry mix: 
Sequence of addition:      Add 1+2+3+4 
Mixer blade    : ON Amperage: Slow Time: 10 min 
Chopper blade: OFF Amperage: --- Time: --- 
 
C) Binder preparation: 
               Add 9gm of PVP K-25 and 3.0gm of SLS in 50gm of purified water and stir well 
with mechanical stirrer for 45 minutes. 
Total Water quantity:  47.5gm + 2.5gm Binder concentration(%w/w): 6.0% 
 
D) Wet granulation: 
Process Mixer blade Chopper blade Amperage Time 
Binder addition ON OFF Slow 1 min 30 sec 
Extra water adiition ON OFF Slow 30 sec 
After binder addition ON ON Slow 5 min 
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E) Wet sieving 
Equipment: Hand mill Screen size: 30# 
 
DRYING: 
 
Equipment: Fluidized bed dryer Temperature: 550c Time: 2hrs 
LOD: NMT 2.0%  (500c for 5min) 
 
A) Dry sieving: 
Equipment: Vibratory siever Sieve no: 30# 
Total Qty : 138.85 Qty retained: 53.25 Qty passed: 85.60 
 
EXTRA-GRANULATION: 
 
Ingredients Qty taken Mesh size Ingredients Qty taken Mesh 
size 
1.MCC pH-101 3.18gm 40# 3.Talc 0.48gm 40# 
2.Aerosil 200 0.48gm 40# 4.Cross povidone XL-10 2.20gm 40# 
Sequence of addition: Dried granules + Above meshed ingredients 
Equipment: Octagonal blender Rotation per minute: 15 Time: 20mins 
 
LUBRICATION: 
                  
Lubricator: Magnesium stearate Qty taken: 1.45gm Mesh size: 60# 
Sequence of addition: Addition of lubricator to extra granulated product 
Equipment: Octagonal blender Rotation per minute: 15 Time: 5mins 
 
Final weight of batch: 146.40gm 
 
 
Percentage yield: 97.6% 
 
CAPSULE FILLING: 
 
 
A) Capsule description: 
Capsule Size: ‘1’                         Colour                   Imprinting 
Body: Green Cap: Green Body: G Cap: G302 
Target wt: 300mg/capsule Wt. of empty capsule: 76 mg 
Total wt. of granules used: 146.40gm No. of capsules required: 500 
 
B) Observation 
Flow on plate: Good Pressing required: Two turns 
Fill Pressure: Normal 
 
No. of capsules filled: 488 
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7.3.9. FORMULATION SHEET 
Product: Fenofibrate capsules Batch size: 500 capsules 
Batch No: F09 Date: xx/yy/zz 
 
DISPENSING: 
 
Ingredients Grade Qty/unit in mg Qty/ batch in 
gm 
1.Fenofibrate Micronised 200.0 100.0 
2.Micro crystalline cellulose Avicel pH-101 27.5 13.75 
3.Starch Unipure F 12.0 6.0 
4.Cross povidone XL-10 16.5 8.25 
5.Poly Vinyl Pyrollidine K-25 18.0 9.0 
6.Crosscarmellose Sodium Ac-Di-Sol 12.0 6.0 
7.Sodium lauryl sulfate --- 9.0 4.5 
8.Collidal silicon dioxide Aerosil 200 1.0 0.5 
9.Talc --- 1.0 0.5 
10.Magnesium stearate --- 3.0 1.5 
11.Purified water --- q.s q.s 
 
GRANULATION: 
 
Equipment used: Rapid mixer granulator Volume: 8L Type: Wet method 
 
A) Sifting: 
Ingredients Qty taken Mesh size Ingredients Qty taken Mesh 
size 
1.Fenofibrate 100gm 40# 4.Cross povidone XL-10 6.0gm 40# 
2.MCC pH-101 10.50gm 40# 5.Ac-Di-Sol 6.0gm 40# 
3.Unipure starch 6.0gm 40# 6.Sodium lauryl sulfate 1.5gm 40# 
 
B) Dry mix: 
Sequence of addition:      Add 1+2+3+4 
Mixer blade    : ON Amperage: Slow Time: 10 min 
Chopper blade: OFF Amperage: --- Time: --- 
 
C) Binder preparation: 
               Add 9gm of PVP K-25 and 3.0gm of SLS in 40gm of purified water and stir well 
with mechanical stirrer for 45 minutes. 
Total Water quantity:  37.5gm + 2.5gm Binder concentration(%w/w): 6.0% 
 
D) Wet granulation: 
Process Mixer blade Chopper blade Amperage Time 
Binder addition ON OFF Slow 1 min 30 sec 
Extra water adiition ON OFF Slow 30 sec 
After binder addition ON ON Slow 5 min 
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E) Wet sieving 
Equipment: Hand mill Screen size: 30# 
 
DRYING: 
 
Equipment: Fluidized bed dryer Temperature: 550c Time: 2hrs 
LOD: NMT 2.0%  (500c for 5min) 
 
A) Dry sieving: 
Equipment: Vibratory siever Sieve no: 30# 
Total Qty : 139.25 Qty retained: 53.85 Qty passed: 85.40 
 
EXTRA-GRANULATION: 
 
Ingredients Qty taken Mesh size Ingredients Qty taken Mesh 
size 
1.MCC pH-101 4.95gm 40# 3.Talc 0.49gm 40# 
2.Aerosil 200 0.49gm 40# 4.Cross povidone XL-10 2.20gm 40# 
Sequence of addition: Dried granules + Above meshed ingredients 
Equipment: Octagonal blender Rotation per minute: 15 Time: 20mins 
 
LUBRICATION: 
                  
Lubricator: Magnesium stearate Qty taken: 1.475gm Mesh size: 60# 
Sequence of addition: Addition of lubricator to extra granulated product 
Equipment: Octagonal blender Rotation per minute: 15 Time: 5mins 
 
Final weight of batch: 147.38gm 
 
 
Percentage yield: 98.25% 
 
CAPSULE FILLING: 
 
 
A) Capsule description: 
Capsule Size: ‘1’                         Colour                   Imprinting 
Body: Green Cap: Green Body: G Cap: G302 
Target wt: 300mg/capsule Wt. of empty capsule: 76 mg 
Total wt. of granules used: 147.60gm No. of capsules required: 500 
 
B) Observation 
Flow on plate: Good Pressing required: Two turns 
Fill Pressure: Normal 
 
No. of capsules filled: 492 
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7.3.10. FORMULATION SHEET 
Product: Fenofibrate capsules Batch size: 500 capsules 
Batch No: F10 Date: xx/yy/zz 
 
DISPENSING: 
 
Ingredients Grade Qty/unit in mg Qty/ batch in 
gm 
1.Fenofibrate Micronised 200.0 100.0 
2.Micro crystalline cellulose Avicel pH-101 27.5 13.75 
3.Starch Unipure F 12.0 6.0 
4.Cross povidone XL-10 16.5 8.25 
5.Poly Vinyl Pyrollidine K-25 18.0 9.0 
6.Crosscarmellose Sodium Ac-Di-Sol 12.0 6.0 
7.Sodium lauryl sulfate --- 9.0 4.5 
8.Collidal silicon dioxide Aerosil 200 1.0 0.5 
9.Talc --- 1.0 0.5 
10.Magnesium stearate --- 3.0 1.5 
11.Purified water --- q.s q.s 
 
GRANULATION: 
 
Equipment used: Rapid mixer granulator Volume: 8L Type: Wet method 
 
A) Sifting: 
Ingredients Qty taken Mesh size Ingredients Qty taken Mesh 
size 
1.Fenofibrate 100gm 40# 4.Cross povidone XL-10 6.0gm 40# 
2.MCC pH-101 10.50gm 40# 5.Ac-Di-Sol 6.0gm 40# 
3.Unipure starch 6.0gm 40# 6.Sodium lauryl sulfate 1.5gm 40# 
 
B) Dry mix: 
Sequence of addition:      Add 1+2+3+4 
Mixer blade    : ON Amperage: Slow Time: 10 min 
Chopper blade: OFF Amperage: --- Time: --- 
 
C) Binder preparation: 
               Add 9gm of PVP K-25 and 3.0gm of SLS in 35gm of purified water and stir well 
with mechanical stirrer for 45 minutes. 
Total Water quantity:  32.5gm + 2.5gm Binder concentration(%w/w): 6.0% 
 
D) Wet granulation: 
Process Mixer blade Chopper blade Amperage Time 
Binder addition ON OFF Slow 1 min 30 sec 
Extra water adiition ON OFF Slow 30 sec 
After binder addition ON ON Slow 5 min 
 
E) Wet sieving 
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Equipment: Hand mill Screen size: 30# 
 
DRYING: 
 
Equipment: Fluidized bed dryer Temperature: 550c Time: 2hrs 
LOD: NMT 2.0%  (500c for 5min) 
 
A) Dry sieving: 
Equipment: Vibratory siever Sieve no: 30# 
Total Qty : 139.65 Qty retained: 54.35 Qty passed: 85.30 
 
EXTRA-GRANULATION: 
 
Ingredients Qty taken Mesh size Ingredients Qty taken Mesh 
size 
1.MCC pH-101 4.95gm 40# 3.Talc 0.49gm 40# 
2.Aerosil 200 0.49gm 40# 4.Cross povidone XL-10 2.20gm 40# 
Sequence of addition: Dried granules + Above meshed ingredients 
Equipment: Octagonal blender Rotation per minute: 15 Time: 20mins 
 
LUBRICATION: 
                  
Lubricator: Magnesium stearate Qty taken: 1.475gm Mesh size: 60# 
Sequence of addition: Addition of lubricator to extra granulated product 
Equipment: Octagonal blender Rotation per minute: 15 Time: 5mins 
 
Final weight of batch: 147.75gm 
 
 
Percentage yield: 98.5% 
 
CAPSULE FILLING: 
 
 
A) Capsule description: 
Capsule Size: ‘1’                         Colour                   Imprinting 
Body: Green Cap: Green Body: G Cap: G302 
Target wt: 300mg/capsule Wt. of empty capsule: 76 mg 
Total wt. of granules used: 147.60gm No. of capsules required: 500 
 
B) Observation 
Flow on plate: Good Pressing required: Two turns 
Fill Pressure: Normal 
 
No. of capsules filled: 493 
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7.4. EVALUATION OF GRANULES: 
 
7.4.1 PHYSICAL PARAMETERS: 
The prepared granules of the formulations were evaluated for the parameters like bulk 
density, tap density, compressibility index, hausner ratio, angle of repose and loss on drying. 
• After granulation, angle of repose was improved. 
• Hausner ratio was found to be 1.2 (or) less than 1.2, shows good flow. 
• Carr's index was found to be in the range of 11 – 16, proves excellent flow property. 
• All these values indicated that the granules have good flow property and hence the 
granulation process has improved the flow property. 
• Loss on drying also within the limit of 2.0%. 
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Table: 7 Physical Parameters of lubricated blend 
Formulation code Angle of Repose (o) Loss on drying Bulk density Tapped density Hausner ratio Carr’s Index 
F1 25.64± 0.762 1.21 ±  0.098 0.350 ±  0.011 0.420 ±  0.002 1.2  ±  0.004 16.6 ±  0.170 
F2 25.56 ±  0.671 1.10 ±  0.085 0.361 ±  0.010 0.430 ±  0.005 1.19 ±  0.002 16.2 ±  0.180 
F3 26.42 ±  0.397 1.12 ±  0.089 0.370 ±  0.012 0.440 ±  0.004 1.18 ±  0.001 15.9 ±  0.181 
F4  25.43 ±  0.754 1.13 ±  0.095 0.350 ±  0.011 0.410 ±  0.006 1.17 ±  0.003 14.63 ±  0.168 
F5 26.42 ±  0.397 1.10 ±  0.095 0.380 ±  0.012 0.450 ±  0.004 1.20 ±  0.002 15.5 ±  0.171 
F6 26.03 ±  0.590 1.11 ±  0.086 0.356 ±  0.011 0.421 ±  0.005 1.18 ±  0.002 15.43 ±  0.065 
F7 26.32 ±  0.310 1.15 ±  0.094 0.361 ±  0.021 0.432 ±  0.002 1.19 ±  0.003 16.43 ±  0.162 
F8 25.98 ±  0.420 1.21 ±  0.098 0.371 ±  0.010 0.412 ±  0.003 1.17 ±  0.004 14.80 ±  0.152 
F9 25.43 ±  0.754 1.15 ±  0.096 0.412 ±  0.012 0.475 ±  0.06 1.15 ±  0.002 15.29 ±  0.181 
F10 25.64 ±  0.953 1.20 ±  0.098 0.361 ±  0.020 0.442 ±  0.003 1.19 ±  0.003 16.07 ±  0.101 
*Values mentioned are average of 3 determinations 
 
RESULTS AND DISCUSSION 
 
Department of Pharmaceutics, K.M. College of Pharmacy, Madurai.                              86 
 
7.4.2 PARTICLE SIZE DISTRIBUTION ANALYSIS: 
     Above 50% of the particle passes through 100mesh size and also less than 0.40% of particles 
retained on 30 mesh size, results in particles having good flow property as well as forms a good 
compressibility index. When the graph is plotted between mesh size Vs percentage of particles 
retained on each mesh gives dumb-bell shape curve. The data are given in table-8. 
7.4.3. RELATED SUBSTANCES:     
            As per ICH as well as USP limit for total impurity of both known and unknown is not more 
than 1.0%. Related substances were carried out by using gas chromatography technique. Related 
substance value for different formulation was under the ICH limits specified in table-8. 
 
 
Fig.11 HPLC Spectrum of Fenofibrate with other Related substances 
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Table:8 Different parameters of lubricated blend 
 
 
Formulation code 
Particle size distribution analysis (%) Related substance  
           (%) 30# 40# 60# 80# 100#    Base 
F1 2.64 15.64 11.36 17.16 12.12 40.92 0.43 
F2 2.04 14.43 12.35 16.16 13.24 41.53 0.53 
F3 1.84 16.44 11.04 17.48 18.22 34.82 0.51 
F4 3.52 16.16 14.40 13.60 9.44 42.28 0.43 
F5 3.05 15.36 15.47 13.80 11.52 40.20 0.46 
F6 3.61 16.15 14.13 13.87 10.53 41.09 0.48 
F7 2.59 16.62 12.37 15.62 11.14 40.18 0.42 
F8 0.52 11.44 5.28 3.10 21.78 57.78 0.47 
F9 0.51 10.24 6.49 3.71 23.17 55.78 0.46 
F10 0.52 9.34 6.33 4.15 22.90 56.66 0.42 
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7.4. EVALUATION OF CAPSULES: 
• The weight variation test was carried out for the capsules, shows within the range of 370mg to 
380mg for individual capsule and the weight variation within 1 to 3%. It passes the test as per USP 
limit. The data was compiled in table-9. 
 
• When the Cap lock length was determined for the capsules shows within the range of 19.0 to 
19.5mm. The observed values are recorded in table-9. 
 
• The content uniformity test was carried out for all the formulations, shows results within the range of 
95% to 105% as per ICH. The observed values are given in table-9. 
Table: 9 Evaluation parameters of capsules 
*Values mentioned are average of 3 determinations 
 
Formulation Code  Weight variation (%) Cap lock length (mm) Content uniformity (%) 
F1 2.7± 0.062 19.2 ±  0.011 97.6 ±  0.701 
F2 2.3±  0.17 19.1 ±  0.010 99.2 ±  0.180 
F3 2.2 ±  0.39 19.0 ±  0.012 98.9 ±  0.181 
F4 2.6 ±  0.07 19.3 ±  0.011 97.6 ±  0.680 
F5 2.4 ±  0.13 19.3 ±  0.012 99.5 ± 0.711 
F6 2.3 ±  0.15 19.4 ±  0.011 99.4 ±  0.651 
F7 2.2 ±  0.31 19.5 ±  0.021 101.4 ±  0.621 
F8 2.3 ±  0.42 19.3 ±  0.010 98.8 ±  0.521 
F9 2.4 ±  0.41 19.0 ±  0.012 100.9 ±  0.181 
F10 2.6 ±  0.33 19.1 ±  0.020 99.0 ±  0.101 
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• Disintegration test was evaluated for capsule as per USP in water, which shows disintegrate in the 
range of 4 mins 30 secs to 6 mins. Time taken for capsule shell broken, content in capsule dissolves, 
capsule shell washout were evaluated. The data was compiled in table -10.  
Table:10 Disintegration time for Formulated capsules 
 
*Values mentioned are average of 3 determinations 
 
 
 
 
Formulation Code 
Disintegration Time for capsule (in minutes) 
Capsule shell broken Content dissolves Capsule shell washout 
F1 1’02’’± 0.062  4’42’’±  0.011 6’02’’±  0.101 
F2 1’13’’±  0.17 4’36’’±  0.010 5’52’’±  0.180 
F3 0’53’’±  0.39 4’54’’±  0.012 6’04’’±  0.181 
F4 0’58’’ ±  0.07 5’02’’±  0.011 5’32’’±  0.180 
F5 0’55’’ ±  0.13 3’58’’±  0.012 4’48’’± 0.171 
F6 1’01’’±  0.15 4’46’’±  0.011 5’12’’±  0.151 
F7 1’12’’±  0.31 4’12’’±  0.021 5’26’’±  0.021 
F8 1’04’’±  0.42 4’03’’±  0.010 4’58’’±  0.121 
F9 0’58’’±  0.41 3’52’’±  0.012 4’37’’±  0.181 
F10 1’00’’±  0.33 4’02’’±  0.020 4’39’’±  0.101 
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7.5. IN VITRO RELEASE OF FENOFIBRATE CAPSULES: 
 
 In formulation F1,F2,F3 formulations Poly Vinyl Pyrrolidine (K-25) was used in concentration 
of 4%, 6%, 8% and surfactant 4.5gm added in dry mix, the release was found to be 83.72%, 86.41% 
and 84.95% respectively. Hence, to improve release rate it was decided to alter the formulation 
further. 
 In F4 formulation PVP K-25 - 6% and surfactant 4.5gm in binder solution was added and 
release was found to be 89.41%. In F5, F6, F7 formulations only surfactant in different concentrations 
in dry mix: binder solution as 1:2, 2:1, 1.5:1.5 were used and release was found to be 96.34%, 
95.44%, 93.36%. 
 To further improvement of dissolution profile, determined the granulation fluid content 
requirement for the effective release. In F8, F9, F10 formulations, addition of purified water for per 
capsule as 100mg, 80mg, 70mg were used and release was found to be 96.56%, 97.22%, 95.40%. 
The percentage of drug release increased with addition of surfactant in 1:2 concentrations and also 
for further improvement, optimized quantity of granulation fluid to be added. Higher dissolution 
profile also due to key role of addition of super disintegrant like crosscarmellose sodium has strong 
swelling property and highly porous structure of PVP K-25. 
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Table: 11 Dissolution data of F1 Formulation: 
S.No. Time (mins) Amount of drug release(mg) 
Percentage drug  
release 
Cumulative % drug
release 
1 10 54.42 27.21 27.21 
2 20 82.84 41.42 41.45 
3 30 136.74 68.37 68.41 
4 40 154.96 77.48 77.55 
5 50 161.24 80.62 80.70 
6 60 167.28 83.64 83.72 
  
 
                       
       
                                                      Fig: 12 Dissolution profile of F1 Formulation 
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Table: 12 Dissolution data of F2 Formulation: 
 
  S.No.   Time(mins) 
Amount of  
drug release(mg) 
   Percentage  
drug release 
Cumulative %  
drug release 
1 10 66.72 33.36 33.36 
2 20 102.94 51.47 51.50 
3 30 133.04 66.52 66.57 
4 40 149.28 74.64 74.71 
5 50 167.82 83.91 83.99 
6 60 172.64 86.32 86.41 
 
             
                Fig: 13 Dissolution profile of F2 Formulation 
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Table: 13 Dissolution data of F3 Formulation: 
 
   S.No.   Time (mins) 
Amount of 
drug release(mg) 
Percentage 
drug release 
Cumulative 
% drug release 
1 10 53.44 26.72 26.72 
2 20 95.68 47.84 47.86 
3 30 141.26 70.63 70.68 
4 40 152.54 76.27 76.34 
5 50 164.72 82.36 82.44 
6 60 169.72 84.86 84.95 
 
           
                                         Fig: 14 Dissolution profile of F3 Formulation 
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Table: 14 Dissolution data of F4 Formulation: 
 
S.No.   Time(mins) 
Amount of 
drug release(mg) 
    Percentage   
    drug release 
Cumulative %  
drug release 
1 10 77.26 38.63 38.63 
2 20 99.02 49.51 49.55 
3 30 144.92 72.46 72.51 
4 40 163.44 81.72 81.80 
5 50 175.82 87.91 88.01 
6 60 178.64 89.32 89.41 
 
                           
                                        Fig: 15 Dissolution profile of F4 Formulation 
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Table: 15 Dissolution data of F5 Formulation: 
 
   S.No.   Time(mins) 
   Amount of 
  drug release(mg) 
    Percentage 
 drug release 
 Cumulative % 
 drug release 
1 10 83.42 41.71 41.71 
2 20 129.84 64.92 64.96 
3 30 156.24 78.12 78.19 
4 40 172.54 86.27 86.35 
5 50 186.64 93.32 93.41 
6 60 192.48 96.24 96.34 
 
                                         
                                                              Fig: 16 Dissolution profile of F5 Formulation 
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Table: 16 Dissolution data of F6 Formulation: 
 
S.No.   Time(mins) 
Amount of 
drug release(mg) 
    Percentage  
  drug release 
 Cumulative % 
 drug release 
1 10 78.16 39.08 39.08 
2 20 124.24 62.21 62.25 
3 30 158.74 79.37 79.43 
4 40 179.08 89.54 89.62 
5 50 185.28 92.64 92.73 
6 60 190.68 95.34 95.44 
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                                             Fig: 17 Dissolution profile of F6 Formulation 
Table: 17 Dissolution data of F7 Formulation: 
 
 S.No.  Time (mins) 
Amount of 
drug release(mg) 
Percentage 
drug release 
   Cumulative %  
drug release 
1 10 74.38 37.19 37.19 
2 20 112.54 56.27 56.31 
3 30 128.74 64.37 64.43 
4 40 177.24 88.62 88.69 
5 50 180.64 90.32 90.41 
6 60 186.52 93.26 93.36 
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                                          Fig: 18 Dissolution profile of F7 Formulation 
 
Table: 1 8 Dissolution data of F8 Formulation: 
 S.No. Time (mins) 
Amount of 
drug release(mg) 
Percentage 
drug release 
Cumulative %  
drug release 
1 10 80.80 40.40 40.40 
2 20 134.38 67.19 67.23 
3 30 160.42 80.21 80.28 
4 40 182.14 91.07 91.15 
5 50 187.42 93.71 93.81 
6 60 192.92 96.46 96.56 
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Fig: 19 Dissolution profile of F8 Formulation 
Table: 19 Dissolution data of F9 Formulation: 
 S.No. Time (mins) 
Amount of 
drug release(mg) 
       Percentage 
drug release 
Cumulative %  
drug release 
1 10 83.80 41.90 41.90 
2 20 116.84 58.42 58.46 
3 30 145.68 72.84 72.90 
4 40 170.82 85.41 85.49 
5 50 187.24 93.65 93.74 
6 60 194.24 97.12 97.22 
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                                         Fig: 20 Dissolution profile of F9 Formulation 
Table: 20 Dissolution data of F10 Formulation: 
 S.No.  Time (mins) 
Amount of 
drug release(mg) 
Percentage 
 drug release 
Cumulative % 
 drug release 
1 10 78.74 39.37 39.37 
2 20 117.82 58.91 58.95 
3 30 164.54 82.27 82.33 
4 40 180.16 90.08 90.17 
5 50 185.42 92.71 92.81 
6 60 190.60 95.30 95.40 
 
                            
                                 
                                                   Fig: 21 Dissolution profile of F10 Formulation 
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Table: 21 Invitro Release Data of Innovator Sample: 
 
S.No.      Time (mins)
Amount of 
drug release(mg)
            Percentage 
         drug release 
Cumulative % 
 drug release 
1 10 76.90 38.45 38.45 
2 20 114.42 57.21 57.25 
3 30 144.88 72.44 72.50 
4 40 170.24 85.12 85.20 
5 50 185.70 92.85 92.94 
6 60 193.44 96.72 96.82 
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Fig: 22 Dissolution profile of Innovator data 
10.6. SIMILARITY FACTOR (F2): 
 When the similarity factor was found out by comparison of formulated product drug release rate 
with Innovator sample drug release rate. Similarity factor data for all the formulation compiled in table-
22. Optimized formulation passes F2 factor. 
Table: 22 Similarity factor for formulated products 
Formulation code F01  F02   F03  F04  F05  F06  F07  F08  F09 F10 
Similarity factor  23.14 34.36 34.56 43.63 54.89 49.78 44.14 68.61 71.12 64.14
 
 
 
7.7. ANALYSIS OF RELEASE DATA: 
Table 23, 24, 25, 26 and Figure 23, 24, 25, 26 below shows the correlation coefficient of 
different kinetic models for fenofibrate optimized (F9) formulation. Higuchi plots were found to 
be of linearity indicated that the drug release mechanism from these capsules by diffusion 
method. Moreover, invitro release of fenofibrate was best explained by Korsmeyer-Peppas 
equation also indicated a good linearity. The release exponent n was 0.491, which indicates a 
coupling of the diffusion and erosion mechanism so called anomalous diffusion or Non-Fickian 
transport. According to Korsmeyer-Peppas equation and indicated that value of “n” in Peppas 
equation is n = 0.45 to 0.89 indicates anomalous diffusion, which implies that the drug follows 
Non-Fickian transport. 
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A) Zero-Order Kinetics Plot: 
Table:23  Zero-Order Kinetics Plot data for optimized (F9) Formulation: 
  Time (mins) Cumulative % drug release 
10 41.90 
20 58.42 
30 72.84 
40 85.41 
50 93.65 
60 97.12 
 
           
                  Fig:23 Zero-order release profile of optimized ( F9) Formulation 
 
 
 
Zero order release kinetics 
R2 0.957 
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B) First-Order Kinetics Plot: 
Table:24  First-Order Kinetics Plot data for optimized (F9) Formulation: 
  Time (mins) Log Cumulative % drug release 
10 1.62 
20 1.76 
30 1.86 
40 1.93 
50 1.97 
60 1.98 
 
 
                           
                                Fig:24 First-order release profile of optimized ( F9) Formulation 
First order release kinetics 
R2 0.904 
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C) Higuchi Plot: 
Table:25  Higuchi Kinetics Plot data for optimized (F9) Formulation: 
  SQRT of Time (mins)  Cumulative % drug release 
3.16 41.90 
4.47 58.42 
5.48 72.84 
6.32 85.41 
7.07 93.65 
7.75 97.12 
 
                    
                          Fig:25 Higuchi release profile of optimized ( F9) Formulation 
 
 
 
Higuchi release kinetics 
R2 0.9893 
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  D)Korsemeyer – Peppas model  Kinetics Plot: 
Table:26  Korsemeyer – Peppas model Kinetics Plot data for optimized (F9) Formulation: 
 LogTime (mins) Log Cumulative % drug release 
1.00 1.62 
1.30 1.76 
1.47 1.86 
1.60 1.93 
1.69 1.97 
1.77 1.98 
 
 
                       
         Fig:26 Korsemeyer – Peppas release profile of optimized ( F9) Formulation 
 
 
Korsemeyer – Peppas model release kinetics 
R2 n 
0.9918 0.4917 
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7.8. DSC Curve: 
 
Fig:27 DSC curve of Fenofibrate API and Optimized formulation 
Fenofibrate peak was clearly seen in its DSC thermogram indicating a sharp 
characteristic peak at temperature range 79-830C corresponding to its melting temperature (Tm). 
This shows that Fenofibrate used was in pure form and indicates the crystalline nature of the 
drug. Also the DSC thermograms for F-09 showed characteristic peak in the same temperature 
range. The DSC analysis of physical mixture of drug and excipients revealed negligible change 
in the melting point of fenofibrate in the presence excipients, indicating no modification or 
interaction between the drug and excipients. 
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7.9. STABILITY STUDY: 
Table:27 Stability study data at 25oC/60%RH  for optimized formulation F09 
S.No. Parameters F09 
                                   25oC/60%RH               
At the end of  
1st month 
At the end of 
2nd month 
At the end of 
3rd  month 
1. Weight Variation (mg)       2.4            2.6           2.5 2.5 
2. Cap lock length (mm)      19.0           19.1          19.2 19.3 
3. Content Uniformity (%)      98.9           99.2          98.9 99.1 
4. Disintegration (mins) 4’37’’ 4’34’’ 4’36’’ 4’35’’ 
5.  
 
Dissolution  
   Profile  
    Data 
Time(mins) Cumulative percentage drug release 
10 41.90 39.60 41.34 40.95 
20 58.42 56.32 57.42 57.32 
30 72.84 73.34 74.14 73.62 
40 85.41 87.31 86.47 86.12 
50 93.65 94.55 93.82 93.75 
60 97.12 97.62 96.99 97.04 
                                             
Fig.28 Comparison of invitro release profile at 25oC/60%RH for 3months 
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Table:28 Stability study data at 30oC/65%RH  for optimized formulation F09 
S.No. Parameters F09 
                                   30oC/65%RH               
At the end of 1st 
month 
At the end of 
2nd month 
At the end of 
3rd  month 
1. Weight Variation (mg)       2.4            2.5           2.4 2.5 
2. Cap lock length (mm)      19.0           19.3          19.0 19.2 
3. Content Uniformity (%)      98.9           99.1          98.7 99.0 
4. Disintegration (mins) 4’37’’ 4’38’’ 4’33’’ 4’35’’ 
5.  
 
Dissolution  
   Profile  
    Data 
Time(mins) Cumulative percentage drug release 
10 41.90 40.60 41.54 40.88 
20 58.42 57.12 58.02 57.94 
30 72.84 72.34 73.54 73.12 
40 85.41 86.61 85.47 85.74 
50 93.65 93.55 94.28 93.12 
60 97.12 97.32 97.09 97.12 
        
                                   Fig.29 Comparison of invitro release profile at 30oC/65%RH for 3months 
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Table:29 Stability study data at 40oC/75%RH  for optimized formulation F09 
S.No. Parameters F09 
                                   40oC/75%RH                
At the end of  
1st month 
At the end of  
2nd month 
At the end of 
3rd  month 
1. Weight Variation (mg)       2.4            2.5           2.8 2.6 
2. Cap lock length (mm)      19.0           19.1          19.0 19.2 
3. Content Uniformity (%)      98.9           99.0          98.7 99.2 
4. Disintegration (mins) 4’37’’ 4’54’’ 4’46’’ 4’40’’ 
5.  
 
Dissolution  
   Profile  
    Data 
Time(mins) Cumulative percentage drug release 
10 41.90 41.32 41.64 41.21 
20 58.42 57.28 56.21 57.12 
30 72.84 72.74 74.14 73.33 
40 85.41 86.11 87.74 86.56 
50 93.65 94.15 94.12 94.02 
60 97.12 97.22 97.18 97.23 
                                      
                         Fig.30 Comparison of invitro release profile at 40oC/75%RH for 3months 
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The optimized F09 formulation was subjected to accelerated stability conditions for 3 
months at 25oC/60% RH, 30oC/65% RH, 40oC/75% RH in a stability chamber (Osworld, 
Mumbai), At the interval of 1 month tablets were withdrawn and evaluated for various 
parameters like weight variation, Cap lock length, content uniformity, disintegration and 
dissolution. The tablets did not show any variation in the tested parameters and the results were 
within the limits. 
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10. CONCLUSION 
BCS Class-II drug, Fenofibrate solubility as well as dissolution profile was improved by 
micronization, addition of surfactant and wet granulation method were prepared and formulated as 
capsule dosage form. Among these, F09 is considered to be the optimized formulation with the desired 
drug release and improved dissolution profile. The polymers which have been used in the best 
formulation (F09) are Polyplasdone, Microcrystalline cellulose, Starch and Poly vinyl pyrollidine with 
small quantity of granulating fluid. 
The micronized fenofibrate analysed by FTIR, Compactibility study, Density parameter 
analysis, Solubility studies, Crystal properties, Particle size, Surface area and Analytical properties 
were evaluated, which shows better results than Non-micronized form. 
The granules were evaluated for Physical parameters, Particle size distribution, Moisture 
content, Contact angle measurement and Related substances determination.  
Dosage form evaluation parameters like Weight variation, Cap lock length indicated that the 
capsules so prepared were physically stable and complied with necessary Pharmacopoeial specification. 
Drug content uniformity also found to be under Pharmacopoeial specification. 
The dissolution of all formulation was carried out as per Pharmacopoeial specification and data 
indicated that dissolution increased in all cases. Also shows that the drug release profile of the final 
optimized formulation was similar to that of marketed innovator product. It can be concluded that 
similar in-vitro release results will give similar in-vivo release profile. 
DSC analysis reveals that there is no physical interaction between drug and excipients so there 
may not be chances of any incompatibility in the formulation. The phenomenon of optimized drug 
release follows Korsemeyer-Peppas model with non-fickian diffusion. 
Stability testing of optimized formulation F09 at 25oC/60 % RH, 30oC / 65% RH, 40oC/75% 
RH for 3 months did not show any variation in the tested parameters and release also. 
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1. INTRODUCTION 
  Modern drug design not only pays attention on biological activity of a drug but also take in to 
account its ability to get absorbed and available in systemic circulation. Since the oral route of drug 
administration is often favored by the patients; therefore the main goal in the process of drug 
development is to obtain a drug product with a good oral bioavailability.  
   Bioavailability is defined as the rate and extent amount of active pharmaceutical ingredients, 
which reaches the systemic circulation from formulated products and also reaches the site of action. 
Oral bioavailability of drug is affected by variety of factor, which influence their absorption from the 
G.I.T. One of the rate determinant factors for absorption is drug dissolution, which is influenced by the 
solubility of the drug in G.I. fluid.  
 The chains of events that occur following administration of solid dosage form until its 
absorption into systemic circulation are depicted in Figure no:1. 
 
 
 
 
Fig.1 Rate determining steps for Bioavailability of drugs 
The two critical rate-determining steps in the absorption of orally administered drugs are1:  
1. Rate of dissolution and 
2. Rate of permeation through biological membrane. 
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1.1 BIOPHARMACEUTICS CLASSIFICATION SYSTEM (BCS) 
 To solve the bioavailability problem US-FDA classified the drugs under 
Biopharmaceutics classification system (BCS) based on the parameters of solubility, 
permeability and dissolution2. The Biopharmaceutics classification system is a scientific 
framework for classifying drug substances based on their aqueous solubility and intestinal 
permeability. According to BCS, drug substances are classified as follows3: 
 
Fig.2 Classification of drugs based on BCS 
CLASS BOUNDARIES4:  
¾ A drug substance is considered HIGHLY SOLUBLE when the highest dose strength is 
soluble in < 250 ml water over a pH range of 1 to 7.5.  
¾ A drug substance is considered HIGHLY PERMEABLE when the extent of absorption in 
human is determined to be > 90% of an administered dose, based on mass-balance or in 
comparison to an intravenous reference dose.  
¾ A drug product is considered to be RAPIDLY DISSOLVING when > 85% of the labeled 
amount of drug substance dissolves within 30 minutes using USP apparatus I or II in a 
volume of < 900 ml buffer solutions.  
INTRODUCTION 
 
Department of Pharmaceutics, K.M. College of Pharmacy, Madurai.                          3 
 
1.2 BCS CLASS-II DRUGS 
                One of the major current challenges of pharmaceutical industry is related to strategies 
that improve the water solubility of poorly soluble drugs. Most of the API’s currently under 
development are BCS class–II compounds. More than one-third of the drugs listed in the U.S. 
Pharmacopoeia fall into the poorly water-soluble categories. For poorly water soluble and highly 
lipophilic drug candidates, dissolution in G.I fluid is the rate-limiting step in absorption. Drug 
substance with an aqueous solubility of less than 1mg/ml may represent a potential 
bioavailability problem, so there is need to improve its solubility5. Poorly water soluble drugs 
often require higher doses in order to reach therapeutic plasma concentrations after oral 
administration. 
This resulting predominance of  BCS class-II compound in pharmaceutical 
development “pipeline” make it apparent that the concept of solubility, the process of dissolution 
must be understood to establish novel strategies for optimization of these factors. The various 
factor, prime importance is drug solubility. Almost every factor that affects dissolution rate, 
influences the drug solubility in one way or other. An empirical relation which is useful to 
predict the dissolution rate of a drug from its solubility is; 
R = dc/dt = 2.24 Cs 
Where, 
                R = dc/dt = dissolution rate of the drug 
                Cs = Saturation or maximum drug solubility 
It has been shown that a drug should have a minimum aqueous solubility of 1% to avoid 
bioavailability problems6. 
Absolute / intrinsic solubility is defined as the maximum amount of solute dissolved in 
a given solvent under standard conditions of temperature, pressure and pH. Solubility is usually 
determined by measuring the concentration of a saturated solution after equilibration at 370C for 
1 hr to 24 hr. The equilibration time depends on the test duration time as well as physical and 
chemical stability of drug7. 
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1.3 TECHNIQUES TO IMPROVE THE SOLUBILITY OF DRUGS 
              Nowadays, pharmaceutical technology provides many approaches to enhance the 
dissolution rate of poorly soluble drugs. To improve the solubility or to increase the availability 
surface area for dissolution is: 
I – Physical modification: 
A) Particle size reduction: 
 Particle size and effective surface area of solid drugs are inversely related to each other. 
Smaller the drug particle, greater the surface area. According to the modified Noyes-Whitney 
equations,  
Dissolution rate = dc/dt = DAKW/O(Cs-Cb)/ Vh 
D – diffusion coefficient of the drug; 
A – Surface area of the dissolving solid; 
KW/O – Intrinsic dissolution rate constant; 
V – Volume of dissolution medium; 
h – Thickness of stagnant layer; 
(Cs-Cb) – Concentration gradient for diffusion of drug. 
  From above equation it is clear that larger the surface area, higher the dissolution rate. 
Since the surface area increases with decreasing particle size, which can be accomplished by 
micronisation or nanonisation, will result in higher dissolution rates. 
         Micronisation is the process involves reducing the size of the solid drug particles to 1 to 
10 microns commonly by spray drying or by use of attrition methods (fluid energy or Jet mill). 
The process is called micro-milling. The solubility of drug is often intrinsically related to drug 
particle size. By reducing the particle size, the increased surface area improves the dissolution 
properties of the drug8. Conventional methods of particle size reduction, such as comminution 
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and spray drying, rely upon mechanical stress to disaggregate the active compound. The 
micronisation is used to increased surface area for dissolution.  
 
Fig.3 Micronisation of drug particles 
        Nanonisation is a process whereby the drug powder is converted to nanocrystal of size 
200-600nm. The main production technologies currently is use to produce drug nanocrystal yield 
as a product a dispersion of drug nanocrystal in a liquid, typically water called nanosuspension. 
Techniques for the production of nanosuspension are homogenization and wet milling. 
       Other techniques for reduction of the particle size are sonocrystallisation, supercritical 
fluid process, spray drying. 
B) Solubilisation9: 
 Surfactants are substances, which at low concentrations adsorb on to the surface or 
intersurface of a system. Surface-active agents have a characteristics structure possessing both 
polar and non-polar regions in the same molecule. Surfactants are classified as follows:  
1. Anionic surfactant (COO-, SO3-, OSO3-): Sodium lauryl sulphate, 
2. Cationic surfactant (N+Cl-): Cetrimide 
3. Ampholytic surfactant: N-deodecyl- N, N- dimethylbetaine 
4. Nonionic surfactant: Poloxamer 
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Fig.4 Effect of surfactant on Drug and biological membrane 
         Surfactant system may change ADME properties of co-administered drug, also penetrate 
and disrupt biological membrane. Anionic surfactant shows enhancements in intrinsic dissolution 
rate of 500 to 2000 fold than in buffer alone. Solubiliztion in surfactant aqueous systems above 
the CMC offers one pathway for the formulation of poorly soluble drugs10. 
 Use of surfactants as absorption enhancer, which enhance both dissolution rate as well as 
permeability of drug. They enhance dissolution rate primarily by promoting wetting and 
penetration of dissolution fluid into the solid drug particles. When small apolar molecules are 
added they can accumulate in the hydrophobic core of the micelles11. It also improves stability 
through micellization. 
 Use of cosolvent system can increase the water solubility of a drug significantly. But the 
choices of biocompatible solvents are limited, such as to glycerine, propylene glycol, 
dimethylsulfoxide, ethanol and N, N dimethylformamide etc. 
 Hydrotropy is a solubilization phenomenon whereby addition of large amount of a 
second solute results in an increase in the aqueous solubility of another solute. Concentrated 
aqueous hydrotropic solutions of sodium benzoate, sodium salicylate, urea, nicotinamide, sodium 
citrate and sodium acetate have been observed to enhance the aqueous solubilities of many 
poorly water-soluble drugs. 
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C) Modification of crystal habit: 
           Depending upon the internal structure of the solid drug, selection of proper form of drug 
with greater solubility is important. In general, amorphous are more soluble than metastable 
polymorphs, anhydrates are more soluble than hydrates and solvates are more soluble than non-
solvates. Amorphous form of the drug demonstrate faster dissolution rate than crystalline 
forms12. 
D)  Complexation 
 The most common complexing ligands are cyclodextrins, caffeine, urea, polyethylene 
glycol, N methylglucamide. cyclodextrin are unique since they increase the water solubility of 
poorly soluble drugs by fitting them into the hydrophobic cavity of the cyclodextrin molecule. 
Thus the molecularly encapsulated drug has greatly improved aqueous solubility and dissolution 
rate. Complexation with cyclodextrin provided superior bioavailability than pure drug13. 
      E) Alteration of pH of the drug microenvironment: 
 This can be achieved in two ways- in situ salt formation, and addition of buffers to the 
formulation e.g buffered aspirin tablets. 
       F) Precipitation: 
 In this method, the poorly aqueous soluble drug such as cyclosporine is dissolved in a 
suitable organic solvent followed by its rapid mixing with a non-solvent to effect precipitation of 
drug in nano size particles. The product so prepared is also called as hydrosol. 
       G) Drug dispersion on carriers: 
 Selective Adsorption on Insoluble Carriers like bentonite can enhance the dissolution 
rate of poorly water soluble drugs by maintaining the concentration gradient at its maximum. 
The two reasons suggested for the rapid release of drugs from the surface of clays are- the weak 
physical bonding between the adsorbate, and hydration and swelling of the clay in the aqueous 
media. The adsorption of drug onto solid adsorbent may chances to reduce the rate and/or extent 
of drug absorption from the GIT14. 
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A solid solution is a binary system comprising of a solid solute molecularly dispersed in 
a solid solvent. Since the two compartments crystallize together in a homogenous one phase 
system, solid solutions are also called as molecular dispersion or mixed crystals. In case of 
reduction in particle size to the molecular level, solid solutions show greater aqueous solubility 
and faster dissolution than eutectics and solid dispersion. They are generally prepared by 
fusion/melt method.  
 Eutectic mixture melts differ from solid solutions in that the fused melt of solute and 
solvent show complete miscibility but negligible solid-solid solubility, i.e., such systems are 
basically intimately blended physical mixture of two crystalline components. 
 Solid Dispersions15 are generally prepared by solvent or co-precipitation method 
whereby both the guest solute and the solid evaporation carrier solvent are dissolved in a 
common volatile liquid solvent such as alcohol. The method is suitable for thermolabile 
substances but has a number of disadvantages like high cost of processing, use of large quantities 
of solvent, difficulty in complete removal of solvent. 
II- Chemical Modification: 
A) Use of salt forms has improved solubility and dissolution characteristics in comparison 
to the original drug. It is generally accepted that a minimum difference of 3 units between 
the pKa value of the group and that of its counter ion is required to form stable salts. 
Alkali metal salts of acidic drugs like penicillin’s and strong acid salts of basic drugs like 
atropine are water-soluble than the parent drug. 
B) Soluble Prodrugs are usually designed to improve oral bioavailability, with poor 
absorption from the gastrointestinal tract usually being the limiting factor. 
1.4 Granulation16: 
Granulation refers to the act or process in which primary powder particles are made to 
adhere to form larger as well as multiparticle entities. Granulation is one of the most important 
unit operations in the production of pharmaceutical oral dosage forms. However, there are many 
different technologies each having different strengths and weaknesses. The selection of 
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granulation type and method depends on drug properties. The method formation of granules are 
graphically shown below. 
 
Fig.5 Steps involved in granulation 
 
Reasons for granulation: 
¾ To prevent the segregation of the constituents of powder mix. Segregation is due to 
differences in the size or density of the component of the mix. 
¾ Granules form a cohesive system will be larger and more isodiametric, and also improve 
flow properties. 
¾ Some powders are difficult to compact to rectify this problem by granulation to be 
employed. 
¾ In case of powder have small size, irregular shape or surface characteristics, are cohesive 
and do not flow well. 
¾ Granules are more stable against humidity and atmosphere and less likely to make cake 
or harden upon standing (less exposed surface area compared to powders). 
¾ To improve the compression characteristics of the mixture and improve the appearance of 
the product.  
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GRANULATION MECHANISMS : 
(A) PARTICLE-BONDING MECHANISMS  
  During granulation, particles adhere and agglomerate due to bond formation. These 
bonds should be strong enough to allow granules to withstand handling without breakdown. 
(B) GRANULE GROWTH MECHANISMS  
  In the dry methods, particle adhesion takes place because of applied pressure. A compact 
or sheet is produced which is larger than the granule size required, and milling and sieving can 
attain therefore the required size. The compact masses are called as slugs, and the process is 
referred to as “slugging”.  
  In wet granulation methods, liquid added to dry powders has to be distributed through the 
powder by the mechanical agitation created in the granulator.  Process of formation of granules 
by different steps like nucleation, transition and ball growth. 
1.5. TYPES OF GRANULATION  
Wet Granulation17 
 Wet granulation, the process of adding a liquid solution to powders, is one of the most 
common ways to granulate. It involves the massing of a mix of dry primary powder particles 
using a granulating fluid. The fluid contains a solvent which must be volatile so that it can be 
removed by drying, and be non-toxic. Typical liquids include water, ethanol and isopropanol 
either alone or in combination. The liquid solution can be either aqueous based or solvent based. 
The steps involved in the preparation of wet granules are graphically shown in Fig no: 6. 
In case of dissolution, Wet granulation of poorly soluble drugs is more superior case than 
dry or other process. The process can be very simple or very complex depending on the 
characteristics of the powders, the final objective of tablet making, and the equipment that is 
available. 
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Fig.6 Steps involved in wet granulation process 
 Ultrafine powder may agglomerate spontaneously when agitated because of the bonding 
effect of vanderwaal’s force and electrostatic forces18. In the traditional wet granulation method 
the wet mass is forced through a sieve to produce wet granules which are subsequently dried. 
The method of preparation of wet granulations by different methods like Fluid bed granulation, 
Pan granulation, Extrusion and palletizing, wet mass using rapid mixer granulator19.  
Dry Granulation20 
  The dry granulation process is used to form granules without using a liquid solution 
because the product to be granulated may be sensitive to moisture and heat. Forming granules 
without moisture requires compacting and densifying the powders. In this process the primary 
powder particles are aggregated under high pressure. The method of preparation of dry 
granulation by either roller compaction or slugging 
Spray Granulation  
The spray fluid bed granulator agglomerates finer particles into larger and free flowing. 
Ingredients are mixed and pre-heated by an upward flow of heated air. Granulation occurs by 
spraying liquid into the fluidized powder. The granules are subsequently dried with heated air. 
The top spray granulator can also be used for top spray coating, layering from liquids and 
instantizing. 
INTRODUCTION 
 
Department of Pharmaceutics, K.M. College of Pharmacy, Madurai.                          12 
 
Melt Granulation 
 In a melt granulation process, the binder solution of a standard wet granulation process is 
replaced with a meltable binder. This binder can be added in molten form, but the high shear 
process offers the benefit of allowing the binder to be added in its solid state. Melting is achieved 
by the energy added through the mixer fraction and the heated jacket of the bowl. 
1.6. ORAL SOLID DOSAGE FORM22  
 The success of therapy depends on selection of appropriate delivery systems as much as it 
depends on drug itself. Oral solid dosage forms are the preferred routes for many drugs and are 
still the most widely used formulations for new and existing release products. Solid dosage forms 
include; powders, granules, tablets, capsules and suppositories. 
 
Advantages of Oral solid dosage forms 
¾ More stable than liquids, with longer expiration dates. 
¾ Easy shipping and handling. 
¾ Less needed shelf space. 
¾ No preservation requirements. 
¾ Accurate dosage (single dose). 
¾ Suitable for sustained release preparation. 
1.7. CAPSULE DOSAGE FORM23  
  Capsules are solid dosage form in which drug is enclosed within either a hard or soft 
container shell. Capsule refers to a range of techniques used to enclose medicines in a relatively 
stable shell. Hard gelatin capsule range from No.5, smallest to No.000, largest. Hard gelatin 
capsule consists of two, telescoping cap and body. The two main types of capsules are: 
o Hard-shelled capsules, which are normally used for dry, powdered ingredients or 
miniature pellets. Hard gelatin capsules are more frequently filled with powders24. 
o Soft-shelled capsules, primarily used for oils and for active ingredients that are 
dissolved or suspended in oil.  
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 Both of these classes of capsules are made from aqueous solutions of gelling agents like: 
Animal protein mainly gelatin or Plant polysaccharides or their derivatives like carrageenans and 
modified forms of starch and cellulose. Other ingredients can be added to the gelling agent 
solution like plasticizers such as glycerin and/or sorbitol to decrease the capsule's hardness, 
coloring agents, preservatives, disintegrants, lubricants and surface treatment25. 
Mechanism of Drug release from Capsule: 
 The steps involved in drug release from capsule shell are – after enter capsules in GIT 
fluid, swelling of capsule takes place, followed by capsule shell broken occur. Then the released 
drug undergoes solubility as well as dissolution occurs.  
 
Fig.7 Mechanism of drug release from capsule shell 
 
Pharmacokinetics of Drug release from capsules: 
 The pharmacokinetic of Drug release from capsules in immediate manner. The immediate 
release of drug from capsules was calculated using this equation: 
 
Where, Css is steady-state plasma concentration (Avg. Cmax); Vd is volume of distribution; F is 
fractional bioavailability.  
INTRODUCTION 
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 The total dose required for immediate release profile was calculated using this equation: 
 
Where, t is time up to which controlled release is required; t1/2 is half life of drug. 
Advantage of Hard gelatin Capsule over other solid dosage form26: 
¾ The bioavailability of solid dosage form to decrease in the order of capsule > tablet > 
coated tablet.  
¾ A capsule dosage form should be quite efficient than other solid dosage form.  
¾ The capsule contents should not be subjected to high compression forces which would 
tend to reduce the effective surface area, thus a capsule should perform better than a 
tablet. 
¾ If a drug is hydrophobic a dispersing agent should be added to the capsule formulation, 
which minimize aggregation and maximize the surface area of the powder. 
¾ The hard gelatin shell should disrupt rapidly and allow the contents to be mixed with the 
G-I tract contents.  
¾ Reduces stability problem with sensitive drugs. 
¾ Easy to swallow and improve patient compliances. 
 
LITERATURE REVIEW 
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2. LITERATURE REVIEW 
 
2.1. LITERATURE REVIEW ON DRUG: 
 
Pamula bhavanam et al., 2010, studied formulation and evaluation of fenofibrate tablets using 
different binding agents were prepared by wet granulation method using sodium lauryl sulfate 
(SLS) and Povidone K-30 as a binding agents with different concentrations. The formulations 
were coded as Feno1 (SLS - 3%, PVP K-30 – 4%) Feno2 (SLS - 3%, PVP K-30 – 4%) and 
Feno3 (SLS - 3%, PVP K-30 – 4%). The formulated products were evaluated for uniformity of 
weight, friability, hardness, thickness, disintegration and dissolution. Among these formulations, 
F- 1 has more dissolution profile than other two formulations27. 
Ravi kumar et al., 2009, designed the formulation of mouth dissolving tablets of fenofibrate 
using sublimation technique by using different subliming agents like camphor, thymol, 
ammonium bicarbonate and different concentrations of menthol. Tablets with menthol at 12.5% 
concentration have shown quick disintegrating features. The in vitro drug release study revealed 
that menthol at a concentration of 12.5 % (F10) of the dosage form weight was able to fast the 
release of Fenofibrate within 10 minutes. Further optimized formulations (F10) were subjected to 
stability testing for 3 months at temperatures 25±5ºC/60±5%RH and 40±5ºC/75±5%RH. In 
conclusion, the results of this technique shows enhancement of the solubility and dissolution rate 
of poorly water-soluble drug like fenofibrate28. 
Ashok patel et al., 2007, formulated a SMEDDS (self-microemulsifying drug delivery system) 
of fenofibrate and evaluated the microemulsification existence area, and the release rate of 
fenofibrate by using Tween 80, PEG 400 in different concentration. The optimized formulation 
for in vitro dissolution and pharmacodynamic studies was composed of Labrafac CM10 (31.5%), 
Tween 80 (47.3%), and polyethylene glycol 400 (12.7%). The SMEDDS formulation can be 
used as a possible alternative to traditional oral formulations of fenofibrate to improve its 
bioavailability29. 
Pasut ratanabanangkoon et al., 2008, developed a novel formulation containing fenofibrate in 
omega-3-oil was developed using a novel throughput screening program. Different concentration 
of omega-3 oil, ethanol and sremophor EL and span 20. Emulsified formulation are prepared 
with 200nm by mild agitation.The optimized formulation Cremophor EL : Span 20 (50:50) tested 
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against the current marketed product Tricor in human healthy volunteers, the new formulation 
showed equivalent to Tricor30. 
Rajeev jain et al., 2008, studied the effect of powder processing on performance of fenofibrate 
formulations, in which powder blending and jet-milling were performed for the production of the 
bulk powders of 200-mg dose orally disintegrating tablets (ODTs) of fenofibrate. The bulk 
powders were granulated followed by blending and tableting. The materials were tested for DSC, 
drug particle sizing post-reconstitution, dissolution, optical micrography, SEM, X-ray 
Spectroscopy and disintegration of the ODTs. It was found that the crystallinity of fenofibrate 
was not impacted by the blending and jet-milling processes. Process A produced materials 
having poorer fenofibrate reconstitution as compared to processes involving jet-milling. It was 
discovered that milling a blend of fenofibrate/excipient (process C) was advantageous over 
milling the raw drug alone (process B). Process C yielded bulk powder that showed rapid 
dissolution and ODTs which exhibited rapid disintegration31. 
Liandong Hu et al., 2010, formulated a microemulsion for oral administration to improve the 
solubility and bioavailability of fenofibrate by using different ratios of oils, surfactants and co-
surfactants (S&CoS) such as capryol, cremphore EL, transcutol. The formulations were 
characterized by solubility of the drug in the vehicles, mean droplet size, stability study and drug 
content. The optimal formulation consists of 25% Capryol 90, 27.75% Cremophore EL, 
Transcutol P 9.25% and water 38% (w/w), with a maximum solubility of fenofibrate up to 
40.96 mg/mL. The pharmacokinetic study was performed in dogs and compared with 
Lipanthy® capsule. The result showed that microemulsion has significantly increased the Cmax 
and AUC compared to that of Lipanthy® capsule (p< 0.05). Results indicated that the 
microemulsions could be used as an effective formulation for enhancing the oral bioavailability 
of fenofibrate32. 
Ganesh et al., 2008, studied the dissolution rate of a poorly water-soluble drug, fenofibrate, is 
increased by adsorbing the drug onto silica. The adsorption is achieved by first dissolving the 
drug in supercritical carbon dioxide and then depressurizing the solution onto silica. Loadings of 
up to 27.5 wt % drug onto silica are obtained. The fenofibrate/silica formulation is free of any 
residual solvent, and carbon dioxide is freely removed upon depressurization. The formulation is 
characterized using IR, UV, X-ray diffraction, DSC and SEM. Based on in vitro dissolution 
study, a significant increase in the dissolution rate ( 80% drug release in 20 min) of drug–silica 
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formulation is observed as compared to micronized fenofibrate ( 20% drug release in 20 min), 
which can be attributed to increase in the surface area and decrease in the crystallinity of drug 
after adsorption onto silica. Two different formulations are compared: (A) amorphous 
fenofibrate/silica and (B) slightly crystalline fenofibrate/silica. The second formulation is found 
to be more stable on storage33. 
Zengrong Jia et al., 2011, formulated a novel solid particle system with a nanomatrix structure 
and without surfactant for the oral delivery of insoluble drugs was prepared. This used a 
combination of pH-sensitive polymethylacrylate and nano-porous silica, in order to improve the 
drug absorption using only pharmaceutical excipients and a relative simple process. The invitro 
drug dissolution and invivo oral bioavailability of this formulation, using fenofibrate as the 
model drug, were compared with other reference formulations such as a suspension, micronized 
formulation or self microemulsion drug delivery system (SMEDDS). The optimal formulation 
was evaluated by SEM, TEM, surface area analysis, DSC, and XRD. The optimized formulation 
prepared with polymethylacrylate (Eudragit®L100-55) and silica (Sylysia®350) markedly 
improved the drug dissolution compared with other reference preparations34. 
Yaping Chen et al., 2009, studied the oral bioavailability of the poorly water-soluble drug 
fenofibrate in liposomes containing a bile salt were used as oral drug delivery systems. 
Liposomes composed of soybean phosphotidylcholine (SPC) and sodium deoxycholate (SDC) 
were prepared by a dry-film dispersing method coupled with sonication and homogenization. 
Invitro release experiments indicated that no more than 20% of total fenofibrate was released 
from SPC/cholesterol (CL) and SPC/SDC liposomes at 2 h, in contrast with near complete 
release for micronized fenofibrate capsules. Strikingly, invivo measurements of 
pharmacokinetics and bioavailability demonstrated higher rates of fenofibrate absorption from 
both SPC/SDC and SPC/CL liposomes than micronized fenofibrate. The disparity between oral 
bioavailability and in vitro release for liposomes strongly suggests alternative absorption 
mechanisms rather than enhanced release. Importantly, SPC/SDC liposomes exhibited a 1.57-
fold increase in bioavailability relative to SPC/CL liposomes, indicating that liposomes 
containing bile salts may be used to enhance oral bioavailability of poorly water-soluble drugs35. 
Markus Vogt et al., 2008, compared several techniques for improving the dissolution of 
fenofibrate, a poorly soluble drug. Particle size reduction was realized by jet milling 
(micronization; cogrinding with lactose, polyvinylpyrrolidone or sodium lauryl sulphate) and by 
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media milling using a bead mill (nanosizing) with subsequent spray-drying. Solid state 
characterization by X-ray diffraction and DSC method. Micronization of fenofibrate enhanced its 
dissolution rate in biorelevant media (8.2% in 30 min) compared to crude material (1.3% in 
30 min). Coground mixtures of the drug increased the dissolution rate further (up to 20% in 
30 min). Commercial products dissolved similarly to crude or micronized fenofibrate, but 
significantly slower than the coground or spray-dried fenofibrate mixtures. The results suggest 
that cogrinding and spray-drying are powerful techniques for the preparation of rapidly 
dissolving formulations of fenofibrate, and could potentially lead to improvements in the 
bioavailability of oral fenofibrate products36. 
Qiao-Ping Huang et al., 2009, studied the solidification process from emulsion, which consisted 
of emulsifier, water and molten drug as oil phase without use of any organic solvent, was firstly 
employed to prepare ultrafine fenofibrate (FF) powder. The effects of stirring speed and volume 
ratios of hot emulsion to cold water on the particle size and morphology were discussed as well 
as the impacts of different emulsifiers on emulsion. The produced ultrafine powder was 
characterized by SEM, XRD, FT-IR, specific surface area analysis and a dissolution test. The 
product had a mean particle size of about 3 μm & specific surface area reached up to 6.23 m2/g, 
which were about 25 folds as large as that of bulk FF. In the dissolution tests, about 96.1% of 
ultrafine FF was dissolved after 120 min, while there was only 38.1% of bulk drug dissolved, 
proving that the dissolution property of ultrafine FF was significantly improved when compared 
to commercial drug37. 
Ming-Thau Sheu et al., 1994, designed the solid dispersion systems of the sparingly water 
soluble drug, fenofibrate in PEG 6000 and PVP were prepared and characterized. The effect of 
particle size of solid dispersions on the dissolution rate was also examined in ethanolic media at 
two stirring rates. An enhancing effect of increasing the proportion of PEG 6000 was achieved 
only for large particles when using a medium containing 60% ethanol with stirring at 100 rpm. 
However, in the same medium but with stirring at 50 rpm, the dissolution rate was reduced with 
the decreasing particle size. As expected, the decrease in drug solubility in the medium 
containing 40 or 50% of ethanol slowed down the dissolution rate of fenofibrate from the PEG 
6000 solid dispersions, and the dissolution rate was also dependent on the particle size. The 
dissolution rate of fenofibrate from the physical mixture was slower than that from the solid 
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dispersion, and decreased with increasing proportion of PEG 6000 incorporated and with 
decreasing particle size. No evidence of a storage effect was obtained38. 
Srinarong et al., 2009, formulated the incorporation of superdisintegrants in solid dispersion 
tablets containing a highly lipophilic drug fenofibrate. In addition, the dissolution rate was more 
increased when the superdisintegrant was incorporated in the drug containing solid dispersions 
than when it was physically mixed with the solid dispersions. The dissolution rate enhancement 
strongly depended on the type of superdisintegrants and increased in the order Polyplasdone® 
XL-10 < Polyplasdone® XL <<Ac-Di-Sol® ≈ Primojel®. The dissolution behavior also depended 
on the type of hydrophilic carriers. Solid dispersion tablets based on inulin 4 kDa, polyethylene 
glycol and polyvinylpyrrolidone K30 showed a much faster dissolution than those based on 
mannitol and hydroxypropyl-β-cyclodextrin. Finally, inulin 4 kDa-based solid dispersion tablets 
showed excellent storage stability, while polyethylene glycol and polyvinylpyrrolidone K30-
based solid dispersion tablets did not39. 
Vinayak et al., 2005, determined whether pH-sensitive polymeric micelles could improve the 
oral bioavailability of a poorly water-soluble drug. Poly(ethylene glycol)-block-poly(alkyl 
acrylate-co-methacrylic acid) used as ionizable polymer. Poorly water-soluble model drugs viz. 
fenofibrate (FNB) and progesterone (PRG) were incorporated in the self-assemblies by the oil-
in-water emulsion or film casting methods. The pH-dependent release of several formulations 
was studied in vitro and the oral bioavailability of FNB-loaded micelles, Lipidil Micro® and 
FNB coarse suspension were assessed in Sprague–Dawley rats at a dose of 7.5 mg/kg. 
Entrapment efficiency ranged between 55–75% and was dependent on polymer composition and 
drug-loading method. Hydrophobic chain composition of the polymer had tremendous impact on 
in vitro release kinetics, with micelles showing the desired pH-dependent drug-release profile. 
The oral bioavailability of FNB from these self-assemblies revealed 156% and 15% increases vs. 
FNB coarse suspension and Lipidil Micro®, respectively. The results suggest that these pH-
sensitive self-assemblies have potential for improving the oral bioavailability of poorly water-
soluble drugs40. 
Michiel Van et al., 2010, studied the effect of release rate from ordered mesoporous silica 
materials on the rate and extent of absorption of the poorly soluble drug fenofibrate. Three 
ordered mesoporous silica materials with different pore diameter (7.3 nm, 4.4 nm and 2.7 nm) 
were synthesized and loaded with fenofibrate via impregnation. Release experiments were 
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conducted under sink conditions and under supersaturating conditions in biorelevant media, 
simulating the fasted and the fed state.  The evaluation was observed in vivo (fasted state): the 
area under the plasma concentration–time profile amounted to 102 ± 34 μM h, 86 ± 19 μM h and 
20 ± 13 μM h for the materials with pore diameter of 2.7 nm, 4.4 nm and 7.3 nm, respectively. 
The results of this, study demonstrate that a decrease in drug release rate – and thus, a decrease 
of the rate at which supersaturation is created – is beneficial to the absorption of fenofibrate41. 
 
2.2. LITERATURE REVIEW ON DOSAGE FORM: 
 
Markus Vogt et al., 2008, studied the oral bioavailability of EMD 57033, a calcium sensitizing 
agent with poor solubility, was compared in dogs using four solid dosage form formulation 
approaches: a physical blend of the drug with excipients, micronization of the drug, preparation 
of coground mixtures and spray-drying of the drug from a nanocrystalline suspension. The 
formulations contained generally accepted excipients such as lactose, hydroxypropylmethyl 
cellulose and SLS in usual quantities. Drug micronization and cogrinding was realized by a jet-
milling technique. All formulations were administered orally as dry powders in hard gelatine 
capsules. While micronization increased the absolute bioavailability of the solid drug 
significantly compared to crude material (from nondetectable to 20%), cogrinding with specific 
excipients was able to almost double this improvement (up to 39%).  It was concluded that 
cogrinding can be a useful tool to improve the bioavailability of poorly soluble drugs from a 
solid dosage form format42. 
Xi Han et al., 2011, studied the simultaneous micronization and surface modification of drug 
particles e.g., to prevent - agglomeration, poor flowability, marginal increase in surface area and 
low bulk density. Particles of ibuprofen (102 μm), a model drug, pre-blended with hydrophilic 
nano-silica, are micronized down to 10 and 5 μm in a continuous fluid energy mill (FEM) to 
obtain fine surface modified particles. Significant improvement in flow properties and 
dissolution rate was observed when micronization accompanied surface modification. 
Additionally, co-grinding with water-soluble polymer during micronization led to further 
increase in bulk density and more enhanced dissolution rate improvement, which is attributed to 
improved wettability. XRD, DSC and Raman were used to examine crystallinity. The surface 
modified, micronized powders also showed improved dispersion, higher bulk densities 
(>0.4 g/ml), reduced electrostatic and higher flowability (FFC ≥ 6) compared to just micronized 
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powder (0.19 g/ml, FFC = 1.0), indicating they may be used in high drug loaded formulations 
amenable to direct compression43. 
Mohammed Barzegar et al., 2010, reported that gliclazide is practically insoluble in water, to 
improve the drug dissolution rate, cogrinding method was used as an approach to prepare 
gliclazide coground/solid dispersions (SDs) in the carriers such as povidone (PVP-K30), 
crospovidone and MCC (Avicel PH 101) with different drug to carrier ratios. The fastest 
dissolution rates were observed from coground formulations with the drug to carrier ratio of 1:5. 
The amount of drug dissolved in 15 min from these SDs was varied from 96% in the case of 
Avicel SD to 100% for SD of PVP. Whereas the amount of drug released in the same time from 
unground drug powder (UD), ground drug powder (GD) and all physical mixtures was between 
60 and 80%. These results indicate that increased wettability and hydrophilicity of drug particles 
and deaggregation brought about by the carriers are the reasons for enhanced drug dissolution 
from the SDs. One of the possible advantages of formulating an insoluble drug such as gliclazide 
is that if it is used in preparation of capsules or tablets of the drug, its dose might be reduced 
which is economically beneficial44. 
S.W.Wong et al., 2006, predicted that surfactant helpful to improve the dissolution rate and 
subsequently the oral absorption and bioavailability of a model poorly water-soluble drug. 
Microparticles containing the model drug (griseofulvin) were produced by spray drying the drug 
in the absence/presence of a hydrophilic surfactant. Poloxamer 407 was chosen as the 
hydrophilic surfactant to improve the particle wetting and the dissolution rate. The results 
obtained showed that the dissolution rate and absolute oral bioavailability of the spray dried 
griseofulvin/Poloxamer 407 particles were significantly increased compared to the control. 
Although spray drying griseofulvin alone increased the drug's invitro dissolution rate, no 
significant improvement was seen in the absolute oral bioavailability when compared to the 
control. Therefore, it is believed that the better wetting characteristics conferred by the 
hydrophilic surfactant was responsible for the enhanced dissolution rate and absolute oral 
bioavailability of the model drug45. 
Markus Vogt et al., 2008, studied the rate of dissolution for four poorly soluble drugs (EMD 
57033, albendazole, danazol and felodipine) was improved by cogrinding them with various 
excipients (lactose monohydrate, corn starch, PVP, HPMC and SLS) using a jet-milling 
technique. Solid state characterization studies by X-ray diffraction and differential scanning 
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calorimetry verified the maintenance of the crystalline state of the active substances after milling. 
In vitro dissolution of the coground mixtures in biorelevant media was much faster than from 
micronised drug in the corresponding physical mixtures for all four compounds. Cogrinding with 
lactose monohydrate resulted in fast dissolution with unstable supersaturation for EMD 57033. 
Cogrinding the same drug with PVP or HPMC produced a more sustained supersaturation. SLS 
accelerated the dissolution of EMD 50733 but inhibited supersaturation. The results suggest that 
the cogrinding with selected excipients is a powerful tool to accelerate the dissolution of poorly 
soluble drugs without converting the drug to the amorphous form or changing the particle size46. 
Stephen B Ruddy et al., 1999, formulated the feasibility of incorporating significant quantities 
of the anionic surfactant, sodium lauryl sulfate (SDS), MCC, mannitol into an immediate release 
tablet formulation of a poorly water-soluble immunosuppressive agent was investigated. Optimal 
in vitro release of the drug from the tablet formulation was achieved by establishing the 
minimum molar uptake ratio necessary to achieve complete micellar solubilization of the drug. A 
model-independent analysis of dissolution results in a reduced volume (250 ml) of modified 
simulated gastric fluid demonstrated that the rate and extent of drug release was highly 
dependent on the mean particle size of the bulk drug, but independent of compression force 
above that required to achieve a compact of acceptable mechanical strength. Employing the 
Korsmeyer–Peppas model of Fickian and non-Fickian drug release, it was further shown that 
release of the drug from the dosage form was governed largely by surface erosion of the 
surfactant-enriched tablet matrix47. 
G. K. Bolhuis et al., 1997, demonstrated that the dissolution from capsules and tablets of poorly 
soluble, hydrophobic drugs can be strongly improved by solid deposition of the drug upon 
hydrophilic, strongly swelling carriers like the super disintegrants sodium starch glycolate and 
croscarmellose sodium. As an effect of its lower swelling power, the super disintegrant 
crospovidone is far less effective than the other super disintegrants. Wet granulation of poorly 
soluble drugs with high concentrations of sodium starch glycolate resulted likewise in a strongly 
improved drug release and bioavailability from capsules and tablets. It was found, however, that 
granules containing a too high concentration of the super disintegrant slow down the drug release 
from tablets. This effect is caused by the formation of a viscous barrier of the super disintegrant 
in the granules during the dissolution process48. 
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Akio Miwa et al., 2000, predicted the amounts of water addition suitable for pharmaceutical 
formulations in wet granulation, using a high-speed mixer or a fluidized bed granulator, before 
granulation trials. In order to determine the suitable amount of water, infrared moisture sensor 
(IR sensor) used to measure the amount of water at the powder surface. Further by analysis the 
plot (output value of the IR sensor vs. amount of added water) for each excipient, the amount of 
water addition for granulation was determined for it. As a second step, two model formulations 
were designed and suitable amounts of water for mixer granulation. Suggested that the above 
method is useful for estimating suitable amounts of addition of water for formulations before 
granulation trials.granulation were predicted by summation of the obtained excipient values. The 
predicted value was compared with the experimental value for high-speed49.  
Beatrice albertini et al., 2003, investigated the use of different excipients, β-lactose and 
polyvinylpyrrolidone of two molecular weights (PVP K12 and PVP K90), in the production of 
improved release piroxicam granules, by wet granulation using  water and steam as granulation 
liquid. The formulations examined were: piroxicam (Px)/β-lactose; Px/PVP K12 and Px/PVP 
K90, each one at a 1:9 weight ratio. Image analysis revealed that β-lactose steam granules had a 
larger surface area with respect to water granules, whereas lower values of this parameter were 
observed in PVP-s granules, confirming the SEM and the fractal analysis results. As regards the 
enhancement of the dissolution profiles, the best result was obtained using β-lactose steam 
granules followed by PVP K12. DSC analysis suggested the partial amorphisation of the drug in 
the granules containing the three excipients. This result was then confirmed by X-ray powder 
diffraction. Therefore, β-lactose and PVP K12 could be proposed as useful excipients to enhance 
the dissolution rate of Px from granules prepared using the granulation technique50. 
Kreutzwald et al., 2007, studied the effect of diluents and disintegrants on the release of poorly 
soluble drugs from hard gelatin capsules. The release of poorly soluble spironolactone depended 
on the solubility of diluents. Dissolution of drug from lactose-based capsules has been observed 
to be pH dependent. Release of spironolactone from microcrystalline cellulose-based capsules 
was similar at pH2 and 6.8. The effect of disintegrant is highly dependent on the 
physicochemical properties of diluents. Release of spirolactone from Verospiron was slower than 
that from lactose-based and microcrystalline based capsules prepared51.  
Ojantakanen et al., 1993, studied the effect of viscosity grade of the polymer diluent on the 
bioavailability of ibuprofen from hard gelatin capsules was evaluated in two single-dose (400 
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mg) cross-over studies in healthy volunteers. The polymers studied were HPMC K100 and 
K15M, and NaCMC (LV, MV and HV). Plain ibuprofen capsules were used for reference. Use 
of HPMC K15M led to sustained drug absorption from the capsules. The tmax and Cmax values 
differed significantly (P < 0.001) from the reference values. The sustaining effect of the lower 
viscosity grade, K 100, was less pronounced. NaCMC-based capsules exhibited sustained-release 
properties similar to those of the HPMC K 100 capsules. In the case of NaCMC, the molecular 
weight of the polymer had no significant effect on drug absorption. No differences in the extent 
of bioavailability of ibuprofen between the formulations studied52. 
Guyot et al., 1996, formulated as a cross-linked with terephtaloyle chloride before being filled 
with pure theophylline powder. The in vitro drug release was carried out on comparison with 
conventional HGC - Dilatrane®. Release profiles showed that cross-linking before or after drying 
of capsules allowed sustained release of drug. The rate of release decreased when the cross-
linking reaction time was increased. When the reaction time was of 30 min, capsules exhibited a 
nearly zero-order release (r = 0.999) with a cumulative drug release of 63.24 ± 10.48% only. 
Cumulative drug release, DT50% and DE from capsules cross-linked before drying had nearly the 
same release characteristics as Dilatrane®53.  
Ambrus et al., 2007, studied the poor aqueous solubility of nifluminic acid (NIF), to improve its 
solubility and dissolution rate through the preparation of formulations based on hydroxypropyl 
β-cyclodextrin (HPβCD) and polyvinylpyrrolidone K25 (PVP K25), a combination of carriers 
which has been advantageously used for a similar purpose with various hydrophobic drugs. 
Ternary systems of NIF, HPβCD, and PVP K25 were prepared in different drug of CD to PVP 
ratios by physical mixing, kneading, microwave irradiation, and co-evaporation. Differential 
scanning calorimetry, thermogravimetric analysis, hot stage microscopy, Fourier transform 
infrared spectroscopy, and X-ray powder diffractometry were used to investigate the resulting 
solid-state interactions. The results showed that the solid state of the drug in the amorphous or 
crystalline ternary combinations of CD to PVP (6:4) influenced both the solubility and the 
dissolution rate of NIF54. 
Badawi A et al., 2011, formulated Itraconazole (ITZ) by a simple solid dispersion method (melt 
method). Binary and ternary ITZ systems were prepared using different polymers including 
crystallization inhibiting polymers (Pluronic F68, Pluronic F127, Eudragit EPO and PVP K25) at 
different ratios. The prepared solid dispersions of itraconazole were characterized by DSC, X-
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Ray diffraction and infrared spectroscopy. All of the prepared systems showed faster and higher 
dissolution rates compared to raw and glassy ITZ. Stability studies of selected systems 
demonstrated that the itraconazole/Pluronic F127/Eduragit EPO (1:1:0.5), T6 ternary system was 
chemically (absence of degradation products) and physically stable (stable dissolution rate and 
negligible change in drug crystallinity) after three months of storage under different conditions55. 
Ahuja et al., 2007, formulated the solid dispersions of rofecoxib with PVP K-25, PEG4000 and 
PEG 6000 in 50%, 75% and 90%w/w were prepared by hot-melt method. The solubility 
efficiency of polymers was in the order of PVP >> PEG 4000 > PEG 6000 due to high 
amorphizing properties of PVP than the PEGs. Significant dissolution improvement was 
observed at the highest carrier amount i.e. 90% and was ascribed to the formation of interstitial 
solid solutions. Drug with PVP K-25 shows better dissolution profile than with other polymer. 
Concluded that, PVP K-25 is better choice for poorly soluble drugs56.  
Sherif IF et al., 2006, Studied the Effect of Wet Granulation on Microcrystalline Cellulose 
Particle Structure and Performance by using MCC alone and with hydroxypropyl cellulose 
(HPC) as a binder were wet granulated by a high-shear process. Result shows decrease in MCC 
compatibility after granulation and also decrease in MCC primary particle porosity and in some 
cases with the formation of large dense granules as well. Effect of milling seems to counteract 
the effect of wet granulation on MCC compatibility57. 
Guo M et al., 2003, Designed to evaluate and compare SMCC's performance to that of other 
excipients commonly used in hard gelatin capsule direct-fill formulations. Four grades of SMCC, 
Anhydrous lactose (direct tableting grade), pregelatinized starch (PGS) (Starch 1500), and 
microcrystalline cellulose (MCC) (Emcocel 90M) were chosen as the control fillers. The 
presence of colloidal silicon dioxide in SMCC not influences the dissolution of these drugs. It 
shows that SMCC could be a suitable direct-fill excipient for hard shell capsule formulations58. 
Simon M et al., 2001, studied Nucleation, growth and breakage phenomena in agitated wet 
granulation processes and also evaluated. Particular emphasis on the fact exist. And also 
explained the majority of experimentally observed behavior of particle rheology. The data 
suggests the formulation properties that control granulation behaviour, such as contact angle and 
dynamic yield strength59. 
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Pathak N et al., 2011, undergone the process optimization research for Disulfiram immediate 
release tablet by dry granulation technique using different fillers, disintegrant and lubrication. 
Poor flow property shown in the formulation with less concentration of Colloidal Silicon 
Dioxide. In the addition of constant concentration of Colloidal Silicon Dioxide shows improved 
flow property and absence of static charges during slugging60. 
Limin shi et al., 2011, determined the evolution of powder tabletability and flowability during 
wetting and nucleation stages of high-shear wet granulation process. Forty-five percent of water 
led to more particle rounding and commencement of nucleation, which impacted tabletability 
and flowability. Enhanced powder flowability achieved by surface smoothing with granule 
rounding as a minor contributor61. 
Biljana G et al., 2011, Investigated to improve the mechanical strength of Paracetamol tablet as 
direct compression. From this study found out the effect of Polyplasdone® XL-10 shows faster 
disintegration time and dissolution rate in comparison with other polymers. Incase of results, 
usage of polyplasdone XL-10 particles is beneficial for the manufacturing of tablets with 
immediate release62. 
Suhas M K et al., 2010, studied losartan potassium to achieve a better dissolution rate and 
further improving the bioavailability by mouth dissolving tablets. Formulated using 
Polyplasdone XL 10, Croscarmellose sodium and Explotab in different concentration and 
evaluated. Among these formulations with 5%w/w Polyplasdone XL 10 release up to 99.26% 
within 12 min shows best results63. 
Venkata ramana., 2009, undergone the research to develop oral disintegrating tablet amlodipine 
besylate using Mannitol, sodium lauryl Sulphate, Aspartame and Acesulfamate used to cosifting 
and serial of blending with other excipients. All the formulation shows low weight different 
disintegration time and rapid in vitro dissolution. The results revealed that the enhanced wetting 
property with addition of SLS and shows faster release profile64. 
Preetha et al., 1998, studied the effect of mode of incorporation of different superdisintegrants 
like croscarmellose sodium, sodium starch glycolate and crospovidone in different soluble drugs. 
All the tablets prepared by wet granulation method. The study reveals that extragranular mode of 
addition seemed to be the best mode of incorporation and improved dissolution profile of the 
formulation65.   
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Garry et al., 1997, Investigated the physiological significance of the invitro drug-excipient 
interaction between croscarmellose sodium NF and weakly basic drugs. In three formulations not 
used starch and Croscarmellose in control, starch alone, Starch & croscarmallose sodium. The 
result shows from the 6 healthy volunteers CONTROL, 22.94 mg; STARCH, 22.41 mg; CROS, 
22.85 mg66. 
Ferrero et al., 2010, Predicted the efficiency of croscarmellose sodium in a direct compression 
formulation containing a poorly water soluble drug. The shortest disintegration time shows the 
mixtures more prone to plastic deformation and densification at same level of applied pressure 
and revealed a finer pore structure. As a result found that the disintegration response in tablets 
formulated with a disintegrant mainly acting by swelling mechanism67. 
Nagasamy V et al., 2006, designed to develop and evaluate sustained release matrix tablets of 
prochlorperazine maleate using HPMC, carbopol and combination of polymers by wet 
granulation technique. The flow and compression characteristics of the prepared granules 
significantly improved by virtue of wet granulation process. Mathematical analysis of the release 
kinetics indicated the nature of the drug release from the matrix tablets by wet granulation 
method obeying first order kinetics68. 
Graham B et al., 2009, studied the properties of amorphous materials and  its manufacture, 
storage and use of medicines. HyperDSC was such that the glass transition (Tg) of 
polyvinylpyrrolidone could be detected in granules and show realistic levels of this binder. The 
result shows that the dissolution of some lactose and that the amorphous binder holding the 
granules together is in fact a solid dispersion. From this study concluded that amorphous particle 
has more stability69. 
Yadhav et al., 2011, Investigated the study to develop a compaction technique to enhance the 
solubility, dissolution rate and other physicochemical properties of poorly water-soluble drugs 
using different polymers like HPMC, Kollicoat IR, Chitosan, PolyvinylPyrrolidone. The 
mechanism for dissolution enhancement is believed to be a microenvironment polymer 
surfactant effect facilitated by keeping the PVP polymers shows better drug dissolution70. 
James D et al., 2011, investigated the binder addition method, affects the growth and properties 
of granules. And also compared the binder distribution using alternative addition methods in both 
high shear mixer and fluidised bed. The result shows that the binder distribution by mass is also 
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investigated and also shows higher binder content in the larger size classes. The majority of 
binder can instead be found around the mean size of the batch71. 
Chowdary et al., 2011, predicted the method to develop nimesulide rapidly dissolving tablet 
formulations by wet granulation and direct compression methods. Nimesulide rapidly dissolving 
tablets with >85% dissolution in 30 min could be formulated employing starch phosphate as 
directly compressible and also with nimesulide-starch phosphate as (1 : 2) solid dispersion by 
wet granulation method shows better biowaiver72.  
Vikas A S et al., 2009, reviewed for complete absorption and good bioavailability of orally 
administered drug and it must be dissolved in gastric fluids. Studied improving solubility and 
dissolution rate by using Polymers, super disintegrants, surfactants are extensively supported 
dissolution enhancement in drugs. The drug with disintegrant and surfactant improves the 
dissolution profile with quicker solubility in gastric fluid73. 
Karen P H et al., 2009, studied the Granulation of hydrophobic powders and its structural 
complexity of new drug molecules. And also studied the wetting and spreading of the fluid 
through the powder particles is a prerequisite for good granulation. The hollow granule structure 
suggests the possibility of using the controlled, open granule structure to manufacture designer 
structured agglomerates with advantageous properties. Research results and observations shows 
that granules are a preliminary framework for liquid marble formation74. 
Musa et al., 2008, studied the intimate physical association between chitosan and silica in 
immediate release formulation.  It shows water uptake, water saturation for gelling formation, 
and compactability among other superdisintegrants. Results have shown that chitosan–silica 
delivers superior performance in wet granulation formulation as a disintegrant75. 
Jen sen wu et al., 2001, investigated effect of codried product of microcrystalline cellulose 
(MCC) with b-cyclodextrin (b-CD) in wet granulation method and effect of lubrication. The 
codried products were lubricated with magnesium stearate in three different percentages (0.2, 
0.5, and 1.0%). The result shows that codried product and Avicels were sensitive to lubrication 
and resulted in decreasing compactibility and increasing disintegration76.  
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3.1. AIM OF WORK 
 
 An antilipemic agent, fenofibrate decreases the levels of fatty substances in the blood.  
Fenofibrate compound belongs to BCS-II classification (drug with very low solubility and has high 
lipophilicity). Dissolution rate of fenofibrate is expected to limit its absorption from GIT. Three 
major approaches available to overcome the bioavailability problem like pharmaceutic, 
pharmacokinetic and biologic approaches. In the objective of present study to enhance dissolution 
of fenofibrate by pharmaceutic method with different approaches like: 
First approach: Micronization by using jet milling with different cycle process such as 1-
cycle, 2-cycle, 3-cycle. 
 
Second approach: Optimize the best binding agent from their different concentration 
 
Third approach: Fix the suitable concentration of surfactant for formulation based on the 
study of extra-granular and intra-granular incorporation. 
 
  Fourth approach: Choose the quantity of binder solution use to get the effective 
formulation.  
 
  Also monitor the different parameters involved in wet granulation process, drying steps and 
capsule filling process. 
 
 Our ultimate goal is to enhance the dissolution profile of poorly soluble drug, fenofibrate 
with simple manufacturing process, lower cost effective, more bioavailability, standard quality and 
higher stability. 
 
 
 
PLAN OF WORK 
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3.2. PLAN OF WORK 
 
The research plan was carried out in the following stages:  
¾ Micronization of fenofibrate by using jet milling in air pressure with different cycle process 
such as 1-cycle, 2-cycle, 3-cycle. 
 
¾ Preformulation studies of micronized fenofibrate with different formulation excipients to 
assess their interaction with the drug and stability of the drug to select suitable excipients. 
 
¾ Development of suitable formulation for micronized fenofibrate by using the selected 
excipients and selected solubility enhancement methods. 
 
¾  Evaluation of Process parameters such as Physical characterization, Weight variation, 
Uniformity content, Disintegration, Cap lock length, Dissolution and Similarity factor along 
with study release characteristics of developed oral solid dosage form. 
 
¾ An optimized formulation showing desired release profile would be selected and stability 
studies would be carried out according to the regulatory guidelines. 
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4. LIST OF MATERIALS AND INSTRUMENTS 
4.1. MATERIALS USED 
 
 
 
 
S.No: MATERIALS NAME OF THE MANUFACTURER 
1. Fenofibrate Harman Finochem, Mumbai.  
2. Microcrystalline cellulose 
    (Avicel pH – 101) 
FMC Biopolymers, U.S.A 
3. Unipure Starch – F National Starch LLC, Thailand. 
4. Croscarmellose sodium 
        (Ac-Di-Sol) 
FMC Biopolymers, U.S.A. 
5. Polyplasdone XL-10 ISP Sales Corp., U.K. 
6. Sodium Lauryl Sulfate Stepan Co, U.S.A. 
7. Poly Vinyl Pyrollidine     
       (PVP K-25) 
ISP Sales Corp., U.K. 
8. Colloidal silicon dioxide FMC Biopolymers, U.S.A. 
9. Talc   Luzenac Pharma, France.  
10. Magnesium Stearate Merck Pharmaceuticals, France. 
11. Purified water Millipore purified, India. 
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4.2. INSTRUMENTS USED 
S.No: INSTRUMENTS NAME OF THE MANUFACTURER 
1. Single pan Electronic balance Ax, Shimadzu – corporation, Japan 
2.  pH meter Mitler Talido, Switzerland 
3. Jet mill Alpine 50 AS, Japan 
4. FT IR- 8400 Shimadzu Corporation, Kyoto, Japan 
5. Tap density apparatus Electro Lab ETD – 1020, India.  
6. LOD Apparatus Sartorius, Germany 
7. UV spectrophotometer1601 Shimadzu – corporation, Japan 
8. X-ray diffractometer Philips PW3710, Japan 
9. Particle size analyzer Malvern, UK 
10. Surface area analyzer Microtrac, US 
11. Melting point apparatus 100 Stanford Research Systems, Inc. US 
12. Rapid mixer granulator S. K. Pharma, India 
13. Fluidized bed dryer S. K. Pharma, India 
14. Capsule filling machine Pankaj industries, India 
15. Particle size distribution Malvern, UK 
16. Vernier calipers Mitutoyo corps, Japan 
17. Dissolution apparatus TDT – 08L, Electrolab, India. 
18. Stability chamber Osworld, Mumbai, India. 
19. DSC analyser-821 Mettler-toledo, Switzerland 
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5.1 DRUG PROFILE 
 
MOLECULAR STRUCTURE OF FENOFIBRATE: 
                      
IUPAC NAME: 
Propan-2-yl,2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoate 
FENOFIBRATE IDENTIFIERS: 
CAS number: 49562-28-9 
Drug Bank: APRD00405 
Category: Anti-Hyperlipidemic 
Bio Pharmaceutical Classification System: Class-II 
CHEMICAL DATA: 
Formula:  C20H21NCLO4    
Mol. Mass: 360.831 g/mol 
Solubility: Less soluble in water 
DESCRIPTION: 
 Fenofibrate is a drug of the fibrate class. Fenofibrate was developed by Groupe Fournier 
SA. It is mainly used to reduce cholesterol levels in patients at risk of cardiovascular disease. 
Like other fibrates, it reduces both low-density lipoprotein (LDL) and very low density 
lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and 
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reducing triglycerides level. It also appears to have a beneficial effect on the insulin resistance 
featured by the metabolic syndrome. It is used alone or in conjunction with statins in the 
treatment of hypercholesterolemia and hypertriglyceridemia. 
PHARMACOKINETIC DATA: 
Absorption 
The absolute bioavailability of Fenofibrate cannot be determined as the compound is 
virtually insoluble in aqueous media suitable for injection. However, Fenofibrate is well 
absorbed from the gastrointestinal tract. Following oral administration in healthy volunteers, 
approximately 60% of a single dose of radiolabelled Fenofibrate appeared in urine, primarily as 
fenofibric acid and its glucuronate conjugate and 25% was excreted in the feces. Peak plasma 
levels of fenofibric acid occur within 6 to 8 hours after administration. 
Distribution 
Upon multiple dosing of Fenofibrate, fenofibric acid steady-state is achieved within 9 
days. Plasma concentrations of fenofibric acid at steady-state are approximately double those 
following a single dose. Serum protein binding was approximately 99% in normal and 
hyperlipidemic subjects. 
Metabolism 
Following oral administration, Fenofibrate is rapidly hydrolyzed by esterases to the active 
metabolite, fenofibric acid; no unchanged Fenofibrate is detected in plasma. 
Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. A 
small amount of fenofibric acid is reduced at the carbonyl moiety to a benzhydrol metabolite 
which is, in turn, conjugated with glucuronic acid and excreted in urine. 
In vivo metabolism data indicate that neither Fenofibrate nor fenofibric acid undergo 
oxidative metabolism (e.g., cytochrome P450) to a significant extent. 
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Excretion 
After absorption, Fenofibrate is mainly excreted in urine in the form of metabolites, 
primarily fenofibric acid and fenofibric acid glucuronide. After administration of radiolabelled 
Fenofibrate, approximately 60% of the dose appeared in urine and 25% was excreted in the 
feces. 
Fenofibric acid is eliminated with a half-life of 20 hours, allowing once daily 
administration in a clinical setting. 
MECHANISM OF ACTION: 
 Fenofibrate is a fibric acid derivative whose lipid modifying effects reported in humans 
are mediated via activation of peroxisome proliferator-activated receptor type alpha (PPARα). 
Through activation of PPARα fenofibrate increases the lipolysis and elimination of atherogenic 
triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production 
of apoprotein CIII.  
TREATMENT FOR CHOLESTEROL DEPOSITION: 
 The mode of action in case of cholesterol deposition in patients by activation of PPARα 
also induces an increase in the synthesis of apoproteins AI and AII, which leads to a reduction in 
very low- and low-density fractions (VLDL and LDL) containing apoprotein B and an increase 
in the high-density lipoprotein fraction (HDL) containing apoprotein AI and AII. In addition, 
through modulation of the synthesis and catabolism of VLDL fractions, fenofibrate increases the 
LDL clearance and reduces small and dense LDL, the levels of which are elevated in the 
atherogenic lipoprotein phenotype, a common disorder in patients at risk for coronary heart 
disease. 
OTHER USES: 
• Fenofibrate has a uricosuric effect 
• Making it of use in the management of gout. 
• It also acts as a blood thinner by lowering the amount of fibrinogen in the blood 
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SIDE EFFECTS: 
 Minor effects like: Headache; nausea. Severe allergic reactions in over dosage condition 
like (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, 
lips, or tongue); calf pain; chest pain; confusion; dark urine; fast, slow, or irregular heartbeat; 
fever, chills, or persistent sore throat; increased coughing or coughing up blood; muscle pain, 
tenderness, or weakness (with or without fever and fatigue); pale stools; red, swollen, blistered, 
or peeling skin; severe or persistent dizziness or lightheadedness; severe or persistent nausea, 
stomach pain, or vomiting; severe pain or swelling in the ankles, feet, or legs; shortness of 
breath; unusual bruising or bleeding; yellowing of the skin or eyes. 
DRUG INTERACTIONS: 
 The following drugs can interact with fenofibrate: 
o A blood thinner such as warfarin (Coumadin); 
o Cyclosporine (Neoral, Sandimmune, Gengraf);  
o Other cholesterol-lowering medicines such as lovastatin (Mevacor), simvastatin (Zocor), 
pravastatin (Pravachol), fluvastatin (Lescol), atorvastatin (Lipitor), or cerivastatin 
(Baycol). 
CONTRAINDICATION:  
 Fenofibrate is contra-indicated in children, during pregnancy or lactation, in patients with 
liver insufficiency, presence of gallstones, renal insufficiency, in patients hypersensitive to 
fenofibrate and/or excipients, known photoallergy or phototoxic reaction during treatment with 
fibrates or ketoprofen 
PREGNANCY AND LACTATION: 
 Fenofibrate has been assigned to pregnancy category C by the FDA. Animal reproductive 
studies with doses 7 to 10 times the recommended human dosage based on body surface area 
(BSA) have demonstrated embryocidal and teratogenic effects. There are no controlled data in 
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human pregnancy. Fenofibrate should be used during pregnancy only if the potential benefit 
justifies the potential risk to the foetus. 
 Animal studies have revealed a potential for tumorigenicity, so considers the use of 
fenofibrate contraindicated in nursing women 
FORMULATIONS: 
 All fenofibrate formulations are available as solid dosage form.  It is under the brand 
name Tricor and Trilipix by Abbott Labs, Lipofen by Kowa Pharmaceuticals America Inc, 
Lofibra by Teva, Lipanthyl, Lipidil, and Supralip by Solvay Pharmaceutical, Fenocor-67 by 
Ordain Health Care, Fenogal by SMB Laboratories, Antara by Oscient Pharmaceuticals, and 
Golip by GolgiUSA. 
COMBINATION WITH OTHER DRUGS: 
 Fenofibrate combination with atorvastatin, shows an increase in the high-density 
lipoprotein fraction (HDL) containing apoprotein AI and AII. It available in brand name as 
(Dyslip, Dysliptin, Atorin,etc.). Other combinational drugs with fenofibrate are Fluvastatin + 
fenofibrate, Allicin + Fenofibrate, Rosuvastatin + Fenofibrate, Etc.  
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 7. EXCIPIENTS PROFILE  
7.1. MICRO-CRYSTALLINE CELLULOSE: 
Non-proprietary names: 
           BP: Micro crystalline cellulose; JP: Micro crystalline cellulose; PhEur: Cellulosum 
microcrystalanium; USPNF: Micro crystalline cellulose 
Synonyms:   
            Avicel PH101, Celex, Cellulose gel, Celphere, Ceolus KG, crystalline Cellulose, 
E460, Emcocel, Ethispheres, Fibrocel, Pharmacel, Tabulose, Vivapur. 
Chemical name: Cellulose 
Empirical Formula: (C6H10O5) n Where n=220   Molecular weight 36000 
Functional category: 
              Adsorbent, suspending agent, tablet and capsule diluent, tablet disintegrant 
Application in Pharmaceutical formulation or technology: 
              Micro crystalline cellulose pH 101 is widely used in pharmaceuticals, primarily as a 
binder/diluent in oral tablet and capsule formulations where it is used in both wet granulation and 
direct compression processes. In addition to its use as a binder/diluent, micro crystalline 
cellulose pH 101 also has some lubricant and disintegrant properties that make it useful in 
tableting. 
Table:1 Uses of Microcrystalline cellulose 
Use Concentration ( % w/w ) 
Anti adherent 5-20 
Capsule binder/diluent 20-90 
Tablet disintegrant 5-15 
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Description: 
              Micro crystalline cellulose pH 101 is purified, partially depolymerised cellulose that 
occurs as a white, odourless, tasteless, crystalline powder composed of porous particles. Its 
commercially available in different particle sizes and moisture grades that have different 
properties and applications. 
Solubility: 
               Slightly soluble in 5 % w/v sodium hydroxide solution, practically insoluble in water, 
dilute acids, and most organic solvents. 
7.2. CROSCARMELLOSE SODIUM:  
Synonyms:  
 Ac-Di-Sol; crosslinked carboxymethylcellulose sodium; modified cellulose gum; Nymcel 
ZSX; Pharmacel XL; Primellose; Solutab; Vivasol. 
Empirical Formula:  
 Croscarmellose sodium is a crosslinked polymer of carboxymethylcellulose sodium. 
Functional Category:  
Tablet and capsule disintegrant. 
Application: 
Croscarmellose sodium is used in oral pharmaceutical formulations as a disintegrant. In 
tablet formulations, croscarmellose sodium may be used in both direct-compression as well as 
wet-granulation processes. When used in wet granulations, the croscarmellose sodium should be 
added in both the wet and dry stages of the process (intra- and extra granularly) so that the 
wicking and swelling ability of the disintegrant is best utilized. Croscarmellose sodium at 
concentrations up to 5% w/w may be used as a tablet disintegrant, although normally 2% w/w is 
used in tablets prepared by direct compression and 3% w/w in tablets prepared by a wet 
granulation process. 
EXCIPIENTS PROFILE 
 
Department of Pharmaceutics, K.M. College of Pharmacy, Madurai.                                    40 
 
Table:2 Uses of Croscarmellose Sodium 
Use Concentration (%) 
Disintegrant of capsules 10-25 
Disintegrant in tablet 0.5–5.0 
 
Description:  
Croscarmellose sodium occurs as an odorless, white or grayish-white powder. 
Acidity/alkalinity: pH = 5.0–7.0 in aqueous dispersions. 
Density (bulk): 0.529 g/ cm3 for Ac-Di-Sol 
Density (tapped): 0.819 g/ cm3 for Ac-Di-Sol 
Density (true):  1.543 g/ cm3 for Ac-Di-Sol 
Particle Size Distribution:   
∗ Ac-Di-Sol: not more than 2% retained on a #200 mesh and not more than 10% retained 
on a #325 mesh. 
∗ Pharmacel XL: more than 90% less than 45 μm, and more than 98% less than100 μm in 
size. 
Solubility:  
Insoluble in water, although croscarmellose sodium rapidly swells to 4–8 times on 
contact with water. Practically insoluble in acetone, ethanol and toluene. 
Stability and Storage Conditions:  
Croscarmellose sodium is a stable though hygroscopic material. A Tablet formulation 
prepared by direct compression, with croscarmellose sodium as a disintegrant, no significant 
difference in drug dissolution after storage at 30°C for 14 months. Croscarmellose sodium 
should be stored in a well-closed container in a cool and dry places. 
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Incompatibilities:  
The efficacy of disintegrants, such as croscarmellose sodium, may be slightly reduced in 
formulations prepared by either the wet-granulation or direct-compression process that contain 
hygroscopic excipients such as sorbitol. Croscarmellose sodium is not compatible with strong 
acids or with soluble salts of iron and some other metals such as aluminium, mercury, and zinc. 
Method of Manufacture:  
Alkali cellulose is prepared by steeping cellulose, obtained from wood pulp or cotton 
fibres, in sodium hydroxide solution. The alkali cellulose is then reacted with sodium 
monochloroacetate to obtain carboxymethylcellulose sodium. After the substitution reaction is 
completed and all of the sodium hydroxide has been used, the excess sodium monochloroacetate 
slowly hydrolyzes to glycolic acid. The glycolic acid changes a few of the sodium 
carboxymethyl groups to the free acid and catalyzes the formation of crosslinks to produce 
croscarmellose sodium. The croscarmellose sodium is then extracted with aqueous alcohol and 
any remaining sodium chloride or sodium glycolate is removed. After purification, 
croscarmellose sodium of purity greater than 99.5% is obtained. The croscarmellose sodium may 
be milled to break the polymer fibers into shorter lengths and hence improve its flow properties. 
Safety:  
Croscarmellose sodium is mainly used as a disintegrant in oral pharmaceutical 
formulations and is generally regarded as an essentially non-toxic and non-irritant material. Oral 
consumption of large amounts of croscarmellose sodium may have a laxative effect, although the 
quantities used in solid dosage formulations are unlikely to cause such problems. 
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7.3. CROSPOVIDONE: 
 Crospovidone XL-10 is a cross linked homo polymer of 1- ethenyl pyrrolidin-10-one. Its 
available in different degrees of powder fineness. 
Molecular formula: (C6 H9 NO)n 
Description: Hygroscopic, White or yellowish white powder. 
Bulk Density: 0.24 – 0.28 gm / cm3 
True Density:  0.35 – 0.45 gm / cm3 
Solubility: Practically insoluble in water, in alcohol and in methylene chloride. 
Stability and storage condition: 
 Crospovidone is a stable and should be stored in a well closed container in a cool and dry 
place. 
Incompatibilities: 
 Crospovidone is incompatible with most organic and inorganic pharmaceutical 
ingredients. When exposed to high water levels, crospovidone may form molecular adducts with 
some materials. 
Handling precautions: 
 Eye protection, glove and a dust mask are recommended. 
Uses: 
 Crospovidone is used in oral pharmaceutical formulation as a disintegrants for capsules, 
tablets and granules.  
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7.4. STARCH: 
Synonyms: Unipure-F; cassava starch; fluftex W; melojel; paygel 55; pure-dent; tablet white. 
Description: 
 It occurs as an odorless and tasteless, fine, white-colored powder comprised of very small 
spherical or ovoid granules whose size and shape are characteristic for each botanical variety. 
Functional category: 
 Glidant; tablet and capsule diluent; tablet and capsule disintegrant; tablet binder. 
Solubility: 
 Practically insoluble in cold ethanol 95%, and cold water. 
pH: 5.5-6.5 
Density (bulk): 0.462 gm/cm3 
Density (tapped): 0.658gm/cm3 
Moisture content: 
 All starches are hygroscopic and rapidly absorb atmospheric moisture 
Stability and storage condition: 
 Dry, unheated starch is stable if protected from high humidity. When used as a diluent or 
disintegrant in solid dosage forms, starch is considered to be inert under normal storage 
conditions. 
Incompatibilities: Nil 
Safety: 
 It is widely used as an excipient in pharmaceutical formulations, particularly oral tablets. 
It is an edible food substance and is generally regarded as an essentially nontoxic and nonirritant 
material. 
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Applications: 
 It is widely used as an excipients primarily in oral dosage formulations where it is 
utilized as a binder diluent and disintegrant. In tablet formulations, freshly prepared starch paste 
is used at a concentration of 5-25% w/w in tablet granulations as a binder. Selection of the 
quantity required in a given system is determined by optimization studies, using parameters such 
as granule friability, tablet friability, hardness, disintegration rate and drug dissolution rate. It is 
one of the most commonly used tablet disintegrants at concentrations of 3-15% w/w. 
 7.5. PURIFIED TALC:  
Synonyms: Hydrous magnesium calcium silicate. 
Chemical Name: Talc. 
Empirical Formula:  Approximate Mg6(Si2O5)4(OH)4 
Functional Category:  
Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule lubricant. 
Application in Pharmaceutical Formulation: 
Table:3 Uses of Purified Talc 
Use Concentration (%) 
Dusting powder 90.0–99.0 
Glidant and tablet lubricant 1.0–10.0 
Tablet and capsule diluent 5.0–30.0 
 
Talc was once widely used in oral solid dosage formulations as a lubricant and diluent. It 
is widely used as a dissolution retardant in the development of controlled-release products. Talc 
is also used as a lubricant in tablet formulations; in a novel powder coating for extended-release 
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pellets; and as an adsorbent. In topical preparations, talc is used as a dusting powder, although it 
should not be used to dust surgical gloves. Talc is a natural material; it may therefore frequently 
contain microorganisms and should be sterilized when used as a dusting powder. Talc is 
additionally used to clarify liquids and is also used in cosmetics and food products, mainly for its 
lubricant properties. 
Description: 
Talc is very fine, white to greyish white, odorless, impalpable, crystalline powder. It 
adheres readily to skin and soft to touch and free from grittiness. 
pH:  7-9. 
Solubility: 
Practically insoluble in dilute acids and alkalis, organic solvents, and water. 
Stability and Storage:  
 Talc is a stable material and may be sterilized by heating at 160°C for not less than 1 
hour. It may also be sterilized by exposure to ethylene oxide or gamma irradiation. Talc should 
be stored in a well-closed container in a cool, dry place. 
Incompatibility:  
It is incompatible with quaternary ammonium compounds. 
7.6. MAGNESIUM STEARATE:  
Synonyms: Magnesium octadecanoate, Octadecanoic acid, Stearic acid. 
Empirical Formula: C36H7OMgO4. 
Molecular Weight: 591.34. 
Application in Pharmaceutical Formulation:  
 Primarily used as lubricant in capsule and tablet at a concentration between 0.25% - 5.0% 
w/w. 
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Description: 
Magnesium stearate is very fine, light white, precipitated or milled impalpable powder of 
low bulk density having a faint order of stearic acid and characteristic taste. The powder is 
greasy to touch and readily adheres to skin. 
Magnesium stearate is hydrophobic and may retard the dissolution of a drug from a solid 
dosage form; the lowest possible concentration is therefore used in such formulations. Capsule 
dissolution is also sensitive to both the amount of magnesium stearate in the formulation and the 
mixing time; higher levels of magnesium stearate and long mixing times can result in the 
formation of hydrophobic powder beds that do not disperse after the capsule shell dissolves. 
An increase in the coefficient of variation of mixing and a decrease in the dissolution rate 
have been observed following blending of magnesium stearate with a tablet granulation. Tablet 
dissolution rate and crushing strength decreased as the time of blending increased and 
magnesium stearate may also increase tablet friability. Blending times with magnesium stearate 
should therefore be carefully controlled. 
Loss on Drying: ≤6.0%. 
Solubility:  
Practically insoluble in ethanol, ethanol (95%), ether and water; slightly soluble in warm 
benzene and warm ethanol (95%). 
Incompatibility:  
  Incompatible with strong acids, alkalis and iron salts. Avoid mixing with strong 
oxidizing materials. Magnesium stearate cannot be used in product containing aspirin, some 
vitamins and most alkaloidal salts. 
7.7. SODIUM LAURYL SULFATE (SLS): 
Synonyms: Sodium octadecyl sulfate, Sodium deodecanesulfate. 
Empirical Formula: NaC12H25SO4;  
EXCIPIENTS PROFILE 
 
Department of Pharmaceutics, K.M. College of Pharmacy, Madurai.                                    47 
 
Molecular Weight: 288.38 g mol-1 
Density: 1.01 g/cm3 
Melting Point: 2060C 
Production of SLS: 
 SLS is synthesized by treating lauryl alcohol with sulfur trioxide gas, or oleum, or 
chlorosulfuric acid to produce hydrogen lauryl sulfate. The industrially practiced method 
typically uses sulfur trioxide gas. The resulting product is then neutralized through the addition 
of sodium hydroxide or sodium carbonate. 
Application in Pharmaceutical Formulation:  
 SLS is used to improve the solubility of lipophilic drugs. Sodium lauryl sulfate is used 
rectally as laxative in enemas, and as an excipient on some dissolvable aspirins and other fiber 
therapy caplets. SLS is mainly used in detergents for laundry and many clearning applications. 
SLS is a highly effective surfactant and is used in any task requiring the removal of oily stains 
and residues. For example, it is found in higher concentrations with industrial products including 
engine degreasers, floor cleaners, and car wash soaps. It is found in toothpastes, shampoos, 
shaving foams, and bubble bath formulations in part for its thickening effect and its ability to 
create a lather. 
Incompatibility: 
Sodium lauryl sulfate diminishes perception of sweetness.  Its more sensitivity, large usage 
results in aphthous ulcer. 
7.8. POLY VINYL PYRROLIDINE: 
Synonyms: PVP, Povidone, Polyvidone, Different grades like K-25, K-30, K-90. 
Empirical Formula: (C6H9NO)n;  
Molecular Mass: 2500 - 25000 g mol-1 
Density: 1.2 g/cm3 
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Melting Point: 150-1800C 
Properties of PVP: 
 PVP is soluble in water and other polar solvents. When dry it is a light flaky powder, 
which readily absorbs up to 40% of its weight in atmospheric water. In solution, it has excellent 
wetting properties and readily forms films. This makes it good as a coating or an additive to 
coatings. 
Application in Pharmaceutical Formulation:  
 The cross-linked form of PVP is used as a disintegrant in pharmaceutical tablets. 
Basically, PVP is a highly cross-linked version of PVP, which makes it insoluble in water but it 
still absorbs water and swells very rapidly and generates a swelling force. That is why it can be 
used as a disintegrant in tablets. PVP can be used as a drug, taken as a tablet or suspension to 
absorb compounds (so-called endotoxins) causing diarrhoea. PVP has E number code E1202 and 
is used as a stabiliser. 
Safety: 
 The U.S. Food and Drug Administration (FDA) has approved this chemical for many 
uses, and it is generally considered safe. However, there have been documented cases of allergic 
reactions to PVP/povidone, particularly regarding subcutaneous (applied under the skin) use and 
situations where the PVP has come in contact with autologous serum (internal blood fluids) and 
mucous membranes. For example, a boy having an anaphylactic response after application of 
PVP-Iodine for treatment of impetigo was found to be allergic to the PVP component of the 
solution. 
7.9. SILICON DIOXIDE: 
Synonyms: Aerosil 200, Fumed silica. 
Empirical Formula: SiO2 
Density: 2.2 g/cm3 
Specific gravity: 2.2 
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Melting Point: 16100C 
Properties: 
 White, amorphous powder of fumed silica, tasteless, odorless, light density powder, 
property of swelling in liquid. Primary particle size is 5–50 nm. The particles are non-porous and 
have a surface area of 50–600 m2/g.  
Production: 
 Fumed silica is made from flame pyrolysis of silicon tetrachloride or from quartz sand 
vaporized in a 3000°C electric arc. 
Application in Pharmaceutical Formulation:  
 Fumed silica serves as a universal thickening agent and a anticaking agent (free-flow 
agent) in powders. Like silica gel, it serves as a desiccant. It is used in cosmetics for its light-
diffusing properties. It is used as a light abrasive, in products like toothpaste. Other uses include 
filler in silicone elastomer and viscosity adjustment in paints, coatings, printing inks, adhesives 
and unsaturated polyester resins.  
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6. EXPERIMENTAL INVESTIGATIONS: 
6.1 PREPARATION OF MICRONIZED FENOFIBRATE API: 
 Micronized fenofibrate was prepared by milling the drug in an Alpine 50 AS jet mill 
operating at 7-8 bar air pressure using a pressurized gas as compressed air and a feed rate of 0.5-
1.0g/min. The milled powders were subjected to the following physical and analytical tests. 
6.2 PREFORMULATION STUDIES77:  
• Preformulation testing is an investigation of physical and chemical properties of drug 
substances alone and when combined with excipients. It is the first step in the rational 
development of dosage forms.  
• The overall objective of preformulation testing is to generate information useful to the 
formulation in developing stable as well as bioavailable dosage forms.  
• The use of preformulation parameters maximizes the changes in formulating an 
acceptable, safe, efficacious and stable product.  
• The drug (Fenofibrate) available in Non-micronised as well as micronized powder form 
and granules were subjected to the following physical and analytical tests. 
 
6.2.1 I.R SPECTRUM FOR FENOFIBRATE78:     
FT-IR spectra of prepared melt granules were recorded on Shimadzu FT IR – 8400 
spectrophotometer (Shimadzu Corporation, Kyoto, Japan). The IR spectrum of substances 
compared with that obtained concomitantly for the corresponding USP reference standard 
provides perhaps the most conclusive evidence of the identity of the substance. Potassium 
bromide (KBr) pellet method was carried out. Fenofibrate (micronized and non-microized) and 
KBr were compressed under 15 tons pressure in a hydraulic press to form a transparent pellet. 
The pellet was scanned from 4000 to 400cm-1 in IR spectrometer. 
 6.2.2 DRUG – EXCIPIENTS COMPATIBILITY STUDIES:   
About 500 mg of micronized fenofibrate alone and mixtures, consisting of micronized 
fenofibrate with various excipients in 1: 1 and 1: 10 ratio in glass vial were taken and kept at 
various accelerated condition [25oC / 60% RH, 30oC / 75% RH, 40oC / 75% RH] in stability 
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chamber. It is carried out for one month in open and closed glass vials. At the interval days of 1, 
2, 3, 4, 5, 6, 14, 21 and 30 days samples were withdrawn and physical characteristics like colour 
change and clumps, if any were recorded. Finally the mixtures with no colour change and no 
clumps were shown for selected formulations.  
PHYSICAL PROPERTIES79: 
 6.2.3 DETERMINATION OF BULK DENSITY AND TAPPED DENSITY:  
 An accurately weighed quantity of the powder (or) granules (W) were carefully poured 
into the graduated cylinder and the volume (Vo) was measured. The graduated cylinder was fixed 
in the density determination apparatus and tapped for 750 times and again subjected to 1250 taps 
till the constant reading was obtained (Vf). The bulk and tap densities were calculated using the 
following formulae.  
Bulk density   =  W / Vo 
Tapped density   =  W/Vf  
W = weight of the powder; Vo = initial volume; Vf = final volume  
 6.2.4 DETERMINATION OF HAUSNER RATIO AND CARR’S INDEX:   
Hausner ratio and the carr’s Index are the measures of interparticle friction and the 
potential powder arch (or) bridge strength and stability respectively which have been widely 
used to estimate the flow properties of powders.  
Hausner ratio and carr’s Index were calculated using the following equation,  
 Hausner ratio    =  
bulk
tap
ρ
ρ
 
carr’s index     =       100x
tap
bulktap
ρ
ρρ −  
 tapρ = tapped density of powder; bulkρ = bulk density of powder  
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6.2.5 DETERMINATION OF ANGLE OF REPOSE :(θ )  
 The pure drug & granules were subjected to angle of repose by funnel method. The 
frictional forces in a loose powder can be measured by the angle of repose,θ . This is the 
maximum angle possible between the surface of a pile of powder and the horizontal plane. The 
angle of repose is calculated by  
θ= tan-1(h/r) 
θ  = angle of repose; h = height of the conical heap; r = radius of the base of the heap. 
 6.2.6 LOSS ON DRYING:  
 It was done in Electronic Loss on Drying (LOD) apparatus (Sartorius, Germany). 
Weighed quantity of 1gm sample was placed in the pan and the temperature was increased to 
50oC for 5mins and the loss on drying in percentage was noted.  
6.2.7 AQUEOUS SOLUBILITY80: 
             Aqueous solubility was determined using the shaker-flask method. Two grams of neat 
drug was added to 50 mL of reagent grade water and was shaken for 24 hours at 25°C ± 1°C. 
Filtered samples were analyzed spectrophotometrically at the wavelength of maximum 
absorption for Fenofibrate drug. Each sample was analyzed in triplicate. 
6.2.8 ANALYTICAL METHODS81: 
 Standard calibration curve of API: 
A) Preparation of 0.05M SLS media: 
  SLS (14.5gm) was accurately weighed and to this distilled water was added to make 
volume upto 1000ml. 
B) Preparation of  Stock solution: 
Fenofibrate API (50mg) was taken in 100ml standard flask and made up to 100 ml with 
0.05M SLS to form primary stock solution. From primary stock solution  2 ml was taken in 100 
ml standard flask and made up to 50 ml with 0.05M SLS to a concentration of 20 mcg / ml. 
 
EXPERIMENTAL INVESTIGATION 
 
Department of Pharmaceutics, K.M. College of Pharmacy, Madurai.                                     53 
 
C) Sample solution : 
From the secondary  stock solution aliquots ranging from 1 to 5 ml were pipetted out and 
diluted to 10 ml with phosphate buffer to get the concentration of 2, 4, 6, 8, 10 mcg / ml the 
absorbance was measured at UV Spectrophotometrically 291nm. 
A standard graph was plotted by keeping the known concentration on X axis and obtained 
absorbance on Y axis. 
CRYSTAL PROPERTIES82: 
6.2.9 PARTICLE SIZE DETERMINATION: 
        The volume mean diameter was measured using low angle laser light scattering. The drug 
particles were suspended in filtered, deionised water containing 0.05% (w/v) polyoxyethylene 
sorbitan monooleate and briefly bath sonicated prior to measurements to ensure there was no 
aggregation. 
6.2.10 SURFACE AREA DETERMINATION: 
         The specific surface area of the Non-micronized and micronized fenofibrate particles was 
determined using a SA3100 Surface Area. Single-point BET determinations by fenofibrate was 
degassed at 60°C owing to their melting points being below 100°C. Surface area calculations 
were made based on the BET equation using the software provided. 
6.2.11 MELTING POINT DETERMINATION: 
          The measurement of melting point involves placing Non-micronized and micronized form 
of fenofibrate API in melting tube and its placed in the well of an electrical melting point 
apparatus and observing the melting through the viewer. 
6.2.12 X-RAY DIFFRACTION (XRD):  
       Pulverized mass of Fenofibrate API was used for XRD studies. The samples were studied 
by using Philips PW3710 X-ray diffractometer. Samples (Non-micronised and micronized 
Fenofibrate) were irradiated by Cu Kα radiation (1.54 Å) and analyzed between 5 to 400. The 
current and voltage applied were 30mA and 40kV, respectively. 
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8.3 FORMULATION CHART: 
Ingredients 
(Qty/unit) in mg 
Optimiztion of 
binder concentration 
Optimization of sodium lauryl 
sulfate concentration 
Optimization of 
granulation  fluid 
F01 F02 F03 F04 F05 F06 F07 F08 F09 F10 
Dry Mixture  
Fenofibrate 200 200 200 200 200 200 200 200 200 200 
      Micro crystalline 
cellulose (Avicel-101) 
27 21 15 30 30 30 30 30 30 30 
Starch (Unipure –F) 12 12 12 12 12 12 12 12 12 12 
Polyplasdone (XL-10) 12 12 12 12 12 12 12 12 12 12 
Croscarmellose 
Sodium (Ac-Di-Sol) 
12 12 12 12 12 12 12 12 12 12 
Sodium lauryl sulfate 9 9 9 --- 6 3 4.5 3 3 3 
Binder Preparation  
PVP K-30 12 18 24 18 18 18 18 18 18 18 
Sodium lauryl sulfate --- --- --- 9 3 6 4.5 6 6 6 
Purified water 90 90 90 90 90 90 90 100 80 70 
Extra-Granulation  
MCC (Avicel pH-101) 6.5 6.5 6.5 6.5 6.5 6.5 6.5 6.5 6.5 6.5 
Polyplasdone (XL-10) 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 
Aerosil 200 1 1 1 1 1 1 1 1 1 1 
Talc 1 1 1 1 1 1 1 1 1 1 
Lubrication  
Magnesium stearate 3 3 3 3 3 3 3 3 3 3 
Total Qty 300 300 300 300 300 300 300 300 300 300 
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6.4. EVALUATION OF GRANULES: 
6.4.1. DETERMINATION OF PHYSICAL PARAMETERS: 
 Formulated granules were subjected to Density parameters like Bulk density, Tapped 
density, Hausner ratio, Compressibility index and angle of repose and Loss on drying was 
performed as per procedure given above (6.2.3-6). 
6.4.2. DETERMINATION OF PARTICLE SIZE DISTRIBUTION: 
 When the formulated granules were subjected to particle size distribution analysis using 
sieve shaker, where the different sieve no. like 30, 40, 60, 80, 100 and pan are used to sieve the 
particles at shaking speed of 50-60 rpm for 5minutes. After sieve shaking calculate the amount of 
particles are retained on each sieve. 
6.4.3. DETERMINATION OF RELATED SUBSTANCE IN GRANULES83: 
As per ICH as well as USP limit for total impurity of both known and unknown is not 
more than 1.0%. Related substances were carried out by using suitable method of High 
performance liquid chromatography technique (Stationary Phase: C18 column, Mobile phase: 
Acetonitrile : Water : Trifluroaceticacid (700:300:1), Flow rate: 1ml/min. Related substance 
impurity calculated by using the formula given below. 
% Impurity = 100 (Ai / Ar) (Cr / Cu) 
Ai – Individual impurity peak area;  
Ar – Fenofibrate peak area; 
Cr – Concentration of fenofibrate formulation;  
Cu – Concentration of fenofibrate raw material. 
\ 
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6.5. EVALUATION OF CAPSULES: 
6.5.1. WEIGHT VARIATION TEST: 
Individual weight of 20 capsules was taken and average weight for 20 capsules was 
calculated. The weight variation between capsules was calculated by using the following formula. 
Weight variation = [(wt. of individual capsule – Avg. wt.) /Avg. wt. of capsules] ×100 
Weight variation should not be more than 7.5% as per USP. 
6.5.2. DETERMINATION OF CAP LOCK LENGTH: 
Cap lock length was tested by vernier calipers. For the Size.1 capsule range is 19.3± 0.4. 
Results are compiled in Table No 9. 
6.5.3. CONTENT UNIFORMITY TEST: 
Standard preparation: 
 Prepare a solution of Fenofibrate working standard in 0.05M SLS having a known 
concentration of about 200 ppm. 
Sample preparation of Fenofibrate capsules: 
 Content of twenty capsules was finely taken and dissolved in small amount of methanol 
shake by mechanical means for 15 minutes, dilute with 0.05M SLS used to get a concentration of 
200 ppm and measured the absorbance at 291nm.  
6.5.4. DISINTEGRATION TEST: 
 The disintegration time was measured by using USP disintegration test apparatus. Six 
capsules were placed in the tubes and the basket was kept in 1-litre beaker of water maintained at 
37±20C. The basket containing capsules move up and down through a distance of 5 to 6cm at a 
frequency of 28 to 32 cycles per minute. The disintegration time for each capsule is as shown in 
Table-10. 
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6.5.5. DISSOLUTION STUDIES84: 
 Release from the capsules was determined in a calibrated USP apparatus 2 (paddle 
method) in 900ml medium operating at 75rpm and 370C. 10ml aliquots were withdrawn at 
different time intervals of 10, 20, 30, 40, 50 and 60 minutes and it was replaced with equal 
volume of fresh medium. The withdrawn samples were filtered through 0.45 micron filter and 
absorbance was measured at 291nm for 0.05M SLS. 
6.5.6. SIMILARITY FACTOR (F2) 85: 
 The values of similarity factor (F2) were used to compare the dissolution profiles of 
optimized experimental batch and reference. The dissolution profiles so obtained were compared 
with the purpose of maximizing the chances of success during the bioequivalence tests. 
                            f2 = 50 + log {[1+ (1/n) ∑t=1 * n (Rt-Tt)2]-0.5 *100} 
 6.5.7. ANALYSIS OF RELEASE DATA86: 
 To analyze the mechanism of release, the best formulation was subjected to some 
statistical tests. The release data obtained were treated according to zero-order (cumulative 
amount of drug release versus time), first-order (log cumulative percentage of drug remaining 
versus time), Higuchi (cumulative percentage of release versus square root of time) and 
Korsmeyer-Peppas (log cumulative percentage of drug released versus time) equation models. 
6.5.8. DSC STUDIES87:  
For the optimized formulation F10 Differential Scanning Colorimetry analysis were 
performed to characterize drug – excipients compatibility. DSC curves were obtained by using a 
DSC-821 (Mettler-toledo, Switzerland), at a heating rate of 5 K//min from 25 to 250oC in a 
nitrogen atmosphere. 
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6.5.9. STABILITY STUDIES88:  
 As per in vitro release formulation F09 was found to be desirable than other formulations. 
Hence it was chosen for stability studies. The capsules were packed and kept for 3 months at 
25oC/60% RH, 30oC/65% RH and 40oC/75% RH in a stability chamber (Osworld, Mumbai). At 
the interval of 1 month capsules were withdrawn and evaluated for physical properties like cap 
lock length, weight variation, moisture content and content uniformity. In vitro drug   release was 
also carried out.  
 
